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While the Copper T intrauterine device (IUD) is one of the most used methods of 
contraception around the world, only 1% of women in sub-Saharan Africa use this method. 
The IUD is a safe and highly effective form of long-acting contraception that provides 
protection for up to 10 years and has a low risk of pregnancy (less than 1% during the first 
year of use). The IUD is highly beneficial in that it can provide protection for women who 
want to delay or space childbearing and unlike methods such as the injectable or oral 
contraceptive, does not require users to make numerous visits to their health care facility or 
obtain a further supply. The IUD is free in the public sector in South Africa, but remains an 
unpopular choice among women. The purpose of this study was to test the effectiveness of a 
brief counselling intervention on the uptake of the IUD among women in Cape Town, South 
Africa. 
 
Part A of this dissertation (Protocol) is comprised of a proposal that was accepted by the 
University of Cape Town (UCT) Human Research Ethics Committee (HREC) and the 
Provincial Government of the Western Cape (PGWC).  It describes the study background and 
methods.  
 
Part B (Literature Review) presents the current state of IUD use in sub-Saharan Africa as 
well as the level of unmet need for contraception in the region. It illustrates the effectiveness 
of the IUD and gives a summary of interventions related to IUD uptake. It also discusses the 
need for increased use of the long acting and permanent methods in sub-Saharan Africa. 
 
Part C (Article) presents the results as a journal article. The incidence of the primary 
outcome was lower than expected. Five percent of women assigned to the control group went 
to family planning to make an appointment for IUD insertion, while 4% of those in the 
intervention group made an IUD insertion appointment. Knowledge of the IUD was not high 
with only 46% of women having heard of the method. After being given a description of the 
IUD, 36% of women said they would consider using the IUD. Twenty-seven percent of 
women stated that they would be interested in receiving an IUD that day. The method was 
not often mentioned to clients as only 16% reported having discussed the IUD with a health 











being aware of the IUD. In this regard, being older and having higher gravidity were both 
significantly associated factors. 
 
The results suggest that IUD is a method that women are interested in learning more about 
and potentially using. It is clear that a more intensive and comprehensive campaign is needed 
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Abbreviations and Acronyms 
 
ART  Antiretroviral Therapy 
CHC  Community Health Centre 
DMPA Depot medroxyprogesterone acetate 
IUD  Intrauterine Device 
LAPM Long Acting or Permanent Methods 
LARC  Long-Acting and Reversible Contraception 
PID  Pelvic Inflammatory Disease 
STI  Sexually Transmitted Infection 
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The Copper T IUD is a safe and effective method for long-term reversible contraception 
(LARC) [1-3]. More than 100 million women around the world use the IUD, making it the 
most utilized method of contraception after sterilisation [2,4]. The IUD offers protection 
against pregnancy for up to 10 years and has a less than 1% risk of pregnancy in the first year 
of use [5]. The IUD is advantageous in that it can provide short-term protection to women 
who want to space their pregnancies, does not require further visits for resupply and requires 
little to no maintenance on the part of the user. It is also a suitable method for women who do 
not desire any more children, but are not prepared for a more permanent method [6]. 
Despite this, less than 1% of women in sub-Saharan Africa use the IUD making it one of the 
areas of the world with the lowest usage [6-7]. While contraception including the intrauterine 
device is free in the public sector in South Africa and South Africa reports the highest use of 
contraception among sub-Saharan African countries, the IUD remains an underutilised choice 
[8]. Two previous studies in Cape Town show levels of IUD use at 5% and 0% respectively 
[10-11]. 
Service delivery challenges, safety concerns and misconceptions about the IUD are just some 
of the barriers that continue to limit IUD use in many developing countries. One of the most 
common reasons for low implementation of the IUD is concern about pelvic inflammatory 
disease (PID) [12]. However, previous studies have not confirmed this belief stating that the 
absolute risk of PID is quite low [2,13]. Studies have also shown the IUD to be safe for use in 
HIV positive women with no significant effects on incidence of PID, HIV progression or 
overall complications [4,14-15]. Studies done among Kenyan and Zambian women 
confirmed that there was a low risk of PID among HIV positive women and showed the IUD 
to be a safe and effective method [4,16-17]. Subsequently, WHO medical eligibility criteria 












[18]. Further barriers include apprehension about rumored side effects like weight loss or 
excessive bleeding and myths about the IUD getting lost in the body or embedded in the 
uterus [6,19]. There is also low knowledge of the IUD among South African women, with a 
previous study reporting that only 41% of participants had heard of the IUD and only 4% had 
ever used it [9]. 
Even in the face of these barriers, South African women have shown an interest in using the 
IUD. In a survey conducted in the Eastern and Western Cape, 89% of participants stated that 
they thought there was a benefit to the IUD and after being given a description of the IUD, 
74% reported that they would consider using it [7]. Given the acknowledged barriers and 
potential interest in IUDs, little is known about how to promote IUD use. Furthermore, there 
is a lack of evidenced-based strategies that can be implemented at the individual level. 
Previous studies in India and Honduras that used educational materials and training to 
promote IUDs showed significant increases in IUD demand as well as knowledge regarding 
the key aspects of the IUD [20-21]. In India, IUD insertions increased from 212 to 247 per 
month and 46 to 106 per month in urban and rural areas respectively, while in Honduras, IUD 
insertions in the intervention group went from a monthly average of 1.12 to 2.0 [20-21]. In 
the United States, an educational intervention among adolescent girls showed an increase in 
the proportion of participants who had a positive attitude toward the IUD (14.7% to 53.8%) 
[22]. However, there is no data on interventions to promote IUD use within South African 
populations. Thus, the purpose of this study is to develop and test an intervention to promote 


















The specific aims of this study are to: 
1. Develop a brief counselling intervention to increase IUD awareness and demand 
among women of reproductive age attending the Gugulethu Community Health 
Centre (CHC). 




Women who receive both the brief counselling intervention in addition to the standard IUD 
educational pamphlet will make more appointments for IUD insertions compared to those 




This randomised intervention study will recruit 100 reproductive-aged women (18-45 years) 




















Recruitment and Enrolment 
 
Figure 1: Trial Flowchart 
 
Participants will be recruited from different waiting room populations at the Gugulethu CHC. 
Women will be identified as potential participants either by referral from a health care 
provider, or by health educators working in the waiting room areas. Upon completion of their 
health care visits, doctors will ask a potential participant if they are interested in learning 
more about family planning options. Potential participants will be women who are not 
pregnant and are in need of a long-acting method. Alternatively, potential participants will be 
approached by health educators and asked the same. Interested participants will be screened 
according to the eligibility criteria. If eligible, they will be referred to study staff for a study 
description, informed consent and baseline questionnaire completion. Participants will then 
be randomised to either the control or intervention group. Those in the control group will 















  Study description 
  Informed Consent 












an IUD. Those in the intervention group will receive the educational pamphlet as well as a 
brief counselling session about the IUD.  
The primary outcome of the study is IUD demand, which will be measured by how many 
women from the control and intervention group undergo IUD insertion.  Accessing records in 




Participants will be non-pregnant, English or Xhosa speaking women attending the 
Gugulethu CHC aged 18-45 years who are able to understand and give informed consent. 
Participants cannot currently be using the IUD, must not be sterilised and interested in a long-
acting method of contraception. 
 
Rationale for Inclusion Criteria 
-18-45 years of age: This is the reproduction age range, thus long-acting contraception is an 
appropriate consideration. 
-Not pregnant: Currently pregnant women will not be eligible for IUD use. 
-Not planning on conceiving for the next two years:  The IUD is most appropriate for women 
who want to space their children and/or delay childbearing. 
-Not sterilised: Women who are sterilised would not be in need of any contraceptive method. 
-Currently using the IUD: Women who are currently using the IUD would not be eligible for 
IUD insertion. 













-Able to give informed consent: All participants must be able to understand the risks, benefits 
and study procedure. 
 
Sample size 
A sample of 100 women will be recruited from the Gugulethu CHC. The required sample size 
was calculated expecting at least a 30% absolute increase in uptake of the IUD (between 30% 
and 60% for the control and intervention group respectively), the primary outcome measure, 
with a precision of 5% and 80% power. A previous study, which had an intervention at the 
community level, reported an absolute increase of approximately 25% [18]. As this is an 




Baseline Questionnaire: All participants will be administered a questionnaire lasting 
approximately 30 minutes. The information collected via the questionnaire will include socio-
demographic and economic information, reproductive health history, current knowledge of 
and attitudes toward the IUD and interest in IUD use. The questionnaires will be 
administered in either English or Xhosa. 
 
IUD Uptake: The amount of women in the experimental and control groups who choose to 
use the IUD will be obtained from records kept by Family Planning. Participants will be 













Pamphlet: All participants will be given an educational pamphlet about the IUD, which will 
explain the characteristics, advantages and disadvantages of the method as well as address 
common myths and/or perceptions regarding the IUD.  
 
Counselling: Women assigned to the intervention group will receive 5-10 minutes of 
counselling regarding the IUD. The counselling will include information about effectiveness, 
benefits, effects on fertility, effects on menstruation and clarification on myths and rumours 
about the IUD. Counselling will also include a display of the IUD and a demonstration of the 
insertion and removal process. 
 
Data Management and Analysis 
All data will be managed and stored in Microsoft Excel with double data entry. Data will be 
analyzed using Stata v10.0 (Stata Corporation, USA). Descriptive statistics will be computed 
and comparisons between participant characteristics and IUD uptake will be made with chi-




The intervention itself poses no physical risks to participants. However, participants who 
choose to undergo IUD insertion may experience side effects such as physical discomfort 
and/or changes in their menstrual cycle. These side effects are not related to participation in 
the study, but rather are part of receiving the family planning modality recommended by the 
study. All side effects of IUD use are explained in the educational pamphlet. Participants will 
be given the contact information for Family Planning services and advised that they may 












insertion. Some participants may find discussing family planning or reproductive health 
history uncomfortable.  
 
Potential Benefits 
All participants will receive information on family planning and contraception as a direct 
benefit. The results of this study will be used to inform future plans to promote IUD use and 
generate demand for contraceptive services.  
 
Informed Consent 
After confirming their interest in taking part in the study, an explanation of the purpose of the 
study, study description and risks and benefits will be given to the participants by the study 
investigator or fieldworker. Patients will be informed that participation is voluntary and that 
declining study entry will not compromise their ability to receive care. The informed consent 
form will also include a clause that grants study staff the permission to access routine health 
care records for each participant. 
Afterwards, informed consent will be obtained from each participant who agrees to take part 
in the study.  Then, they will be assigned a participant ID number and proceed to begin the 
questionnaire. Written consent will be available in both English and Xhosa. Study staff will 
conduct verbal consent for participants with low literacy with confirmation gained to ensure 
that participants understand all risks, benefits and study procedures. 
 
Privacy and confidentiality 
Participants will be informed that for outcome measurement their names and folder numbers 
must be recorded on the questionnaire. Participant ID numbers assigned during the informed 












publication of the study. To maintain confidentiality, all interviews will be conducted in a 
private room. Study staff will reiterate that all information shared via the questionnaire or 
during counselling will be kept strictly confidential. All participant files will be kept in a 
locked cabinet when not being accessed by study staff. 
 
Remuneration 
Participants will receive no remuneration for participating in the study. 
 
Timeline 
It is anticipated that approximately 5 participants can be recruited per day, thus the study will 










































1. Hofmeyr GJ, Singata M, Lawrie TA. Copper containing intra-uterine devices versus depot 
progestogens for contraception. Cochrane Database of Systematic Reviews. 2010. Issue 6. 
Art. No.: CD007043. DOI: 10.1002/14651858.CD007043.pub2. 
 
2. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device 
increase the risk of pelvic inflammatory disease among women with sexually transmitted 
infection? A systematic review. Contraception 2006;73:145-153. 
 
3. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: 
lessons learned. Contraception 2007;75:S55-S59. 
 
4. Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the 
intrauterine device appropriate contraception for HIV-1-infected women? Brit J Obstet 
Gynaec 2001;108:784-790. 
 
5. Hatcher RA, Rinehart W, Blackburn R, Geller JS, Shelton JD. The Essentials of 
Contraceptive Technology. 5th ed. Baltimore: Johns Hopkins Bloomberg School of Public 
Health, Population Information Program; 1997. 
 
6. Katz KR, Johnson LM, Janowitz B, Carranza JM. Reasons for the Low Level of IUD use 
in El Salvador. Int Fam Plan Perspec 2002;28(1):26–31. 
 
7. Gutin SA, Mlobeli R, Moss M, Buga G, Morroni, C. Survey of knowledge, attitudes and 
practices surrounding the intrauterine device in South Africa. Contraception 2011;83:145-
150. 
 
8. United Nations Department of Economic and Social Affairs Population Division. World 
Contraceptive Use 2011. [cited 2012 June 12]. Available from: 
http://www.un.org/esa/population/publications/contraceptive2011/contraceptive2011.htm. 
 
9. van Zijl S, Morroni C, van der Spuy ZM. A survey to assess knowledge and acceptability 
of the intrauterine device in the Family Planning Services in 
Cape Town, South Africa. J Fam Plann Reprod Health Care 2010; 36(2):73–78. 
 
10. Glasier AF, Smith KB, van der Spuy ZM, Ho PC, Cheng L, Dada 
K, et al. Amenorrhea associated with contraception – an international study on acceptability. 
Contraception 2003; 67:1–8. 
 
11. Glasier AF, Smith KB, Cheng L, Ho PC, van der Spuy Z, Baird DT. An international 
study on the acceptability of a once-a month pill. Hum Reprod 1999; 14: 3018–3020. 
 
12. Shelton J. Risk of clinical pelvic inflammatory disease attributable to an 
intrauterine device. The Lancet 2001; 357(9254):443. 
 
13. Meirik O. Intrauterine devices — upper and lower genital tract infections. Contraception 
2007;75:S41-S47. 
 












contraception for women with HIV/AIDS: a systematic review. AIDS 2009;23(suppl 1):S55-
S6 
 
15. Mitchell HS, Stephens E. Contraception choice for HIV positive women. Sex Transm 
Infect 2004;80:167–173. 
 
16. Sinei SK, Morrison CS, Sekkade-Kigondu C, Allen M, Kokonya D. Complications of use 
of intrauterine devices among HIV-1-infected women. Lancet 1998;351:1238-41. 
 
17. Stringer EM, Kaseba C, Levy J, Moses S, Goldenberg RL, Chi BH, et al. A randomized 
trial of the intrauterine contraceptive device vs hormonal contraception in women who are 
infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007;197:144.e1-
144.e8. 
 
18. World Health Organization. Improving access to quality care in family planning: medical 
eligibility criteria for contraceptive use, 4th edition. Geneva: WHO Press; 2010. 
 
19. Osei I, Birungi H, Addico G, Askew I, Gyapong JO. What Happened to the IUD in 
Ghana? Afr J Reprod Health 2005;9(2):76-91. 
 
20. Khan ME, Kar SS, Desai VK, Patel P, Itare BP, Barge, S. Increasing the Accessibility, 
Acceptability and Use of the IUD in Gujarat, India. Population Council, Frontiers in 
Reproductive Health. 2008.  
 
21. Flores IF, Fonseca ERA, Flores RM, Vernon R, Solorzano J, Pavon S, et al. Increasing 
use of the IUD through Community and Clinic based Education Activities in Rural Honduras. 
Population Council, Frontiers in Reproductive Health. 2007.  
 
22. Whitaker AK, Terplan M, Gold MA, Johnson L, Creinin MD, Harwood B. Effect of a 
Brief Educational Intervention on the Attitudes of Young Women Toward the Intrauterine 

















Search Strategy ..................................................................................................................4 
Effectiveness of the IUD ....................................................................................................5 
Barriers to promoting the IUD in sub-Saharan Africa ..................................................6 
Risk of Pelvic Inflammatory Disease ...............................................................................6 
Rumors and Myths about the IUD ...................................................................................8 
Health System Barriers .....................................................................................................9 
Interventions to promote the IUD in sub-Saharan Africa ...........................................10 
Supply-Demand-Advocacy Interventions ......................................................................10 
Community-based contraceptive counseling .................................................................14 
IUD use for HIV positive women ....................................................................................14 
Investing in LAPMs in sub-Saharan Africa ..................................................................16 
References .........................................................................................................................18 
Tables 














While South Africa reports the highest use of contraception in sub-Saharan Africa, it, like 
many other countries in the region, faces a high unmet need for contraception. In sub-
Saharan Africa alone, there are approximately 14 million unintended pregnancies every 
year [1]. Statistics from the Demographic and Health Surveys (DHS) show that the 
majority of countries report levels of unmet contraceptive need exceeding 20% and some 
even 30% [2]. Approximately 25 million women in sub-Saharan Africa have no access to 
modern means of contraception [2].  Contrast these figures to those of Asia and Latin 
America where 48% and 63% of women, respectively, use a modern method of 
contraception and based on such comparisons it is clear that well functioning and 
comprehensive family planning programs are needed in sub-Saharan Africa. Moreover, 
the total fertility rate (TFR) of the region is more than twice that of Asia and Latin 
America, with some countries having an average TFR of six births per woman [2].  
As it is in many other regions of the world, family planning in sub-Saharan Africa is 
fraught with cultural implications. There is a high value placed on having children and on 
having large families in order to pool resources [3]. Talking about family planning can 
also be difficult so women often prefer more covert methods of contraception such as the 
injectable [4]. Furthermore, many countries in the region practice a traditional method of 
spacing births, which makes non-permanent methods more favourable [4-5]. Of the 
modern methods of contraception used, approximately 25.7% of sub-Saharan African 
women report using the injectable [3]. 
Besides being discreet, methods like the injectable may also be seen as more practical. 
There are fewer concerns about adherence and it does not require much training in 












acting or permanent methods (LAPMs) such as the IUD, sterilisation and implants has 
been underestimated in regions such as sub-Saharan Africa. This has resulted in little 
consideration being given to these methods as crucial elements of family planning 
programmes [6-7]. 
Previous research shows that sub-Saharan Africa has the lowest level of IUD usage 
globally, with reports putting it at approximately 1% [8]. However, in the context of sub-
Saharan Africa contraceptive needs, the IUD would be a great method as it is 
inexpensive, long lasting but not permanent and discreet. The fact that it requires training 
on the part of the health worker continues to be a barrier to its implementation. 
Furthermore, surveys have shown that in South Africa, myths and rumors surrounding the 
IUD also contribute to its underutilisation [8].  
Adding more LAPMs like the IUD to contraceptive choices would likely increase the 
overall uptake of contraception. This has proved to be the case in several studies where 
more contraceptive method options increased overall contraceptive uptake [9-11]. There 
have also been concerns about a possible link between injectable contraception and 
increased risk of HIV acquisition or transmission [12]. As the Copper T IUD is non-
hormonal, it could be a valuable contraceptive option for HIV positive women if the link 
is proven to be true. Moreover, the safety of oral contraceptives among HIV positive 
women on antiretroviral therapy (ART) is also uncertain. These concerns are heightened 
in a region like sub-Saharan Africa where an estimated 14 million HIV positive women 
live [13]. 
The IUD is a potentially valuable contraceptive option to women in sub-Saharan and 












reversible contraception. This paper will review the effectiveness of the IUD, barriers to 
IUD use, interventions to promote IUD use, IUD use among HIV positive women and the 
case for investing in LAPMs in sub-Saharan Africa. 
 
Search Strategy 
The following terms were utilised to search for appropriate literature on the 
study topic. All studies which had the following terms were explored. The references 
used in those studies were further explored to reach those studies relevant to the literature 
review objectives. 
The following terms were used to search for studies which met the objectives of the 
literature: 
 
 IUD and Africa, intrauterine device and Africa 
 IUD and intervention, intrauterine device and intervention 
 IUD and barriers, intrauterine device and barriers 
 IUD and HIV, intrauterine device and HIV 
 IUD and effectiveness, intrauterine device and effectiveness, efficacy 
 Long acting permanent methods and sub-Saharan Africa, LAPM and sub-Saharan 
Africa 
 Search engines: PubMed, EbscoHost, ScienceDirect, JSTOR, Google and  Google 
scholar 
 
Criteria for considering studies to promote the IUD in sub-Saharan Africa 
Types of studies 
Studies considered were randomized trials and before and after studies which compared 
an intervention with the current standard of care. Studies must have taken place in sub-














Types of participants 
Participants of reproductive age were eligible.  
 
Types of Interventions 
Interventions chosen aimed to improve contraceptive use and included counseling and 
information provided via educational materials, radio, tv and other media. Studies which 
measured IUD uptake as an outcome were included. 
 
Effectiveness of the IUD 
Both the copper T IUD and the levonorgestrol IUD are highly effective methods for 
preventing pregnancy with estimates of the copper T ranging from 0.6 to 0.8 pregnancies 
per 100 woman-years [14], and  0.2 per 100 woman-years for the Mirena [14]. Studies 
have found the IUD to be more effective then the contraceptive pill, transdermal patch, 
vaginal ring or DMPA. For example, a cohort study of 7,486 women from the United 
States, found that long-acting reversible contraception or LARC (IUDs and implants) had 
a contraceptive failure rate of 0.27 per 100 participant-years compared to 4.55 among 
women using the pills, patch or ring (p <.001) [15].  Similarly, a Cochrane review of 
women from Zambia, Brazil, Guatamala, Vietnam and Egypt, found the copper T was 
more effective at preventing pregnancy than depot progestogens (risk ratio (RR) 0.47; 
95% confidence interval (CI) 0.26 to 0.85) [16]. In fact, the IUD (both copper and 
hormonal) has been shown to be the most effective female contraceptive method after 
tubal ligation [17]. 
 
Studies have shown the Copper T IUD to be very efficacious with regards to pregnancy 












became pregnant and in a comparative study, 2.1 women per 100 became pregnant during 
the first ten years of use [18]. In a systematic review, the TCu380A or TCu380S IUD was 
found to be the most effective of all the copper framed intrauterine devices [19]. The 
Copper T IUD is approved for up to 10 years of use, but studies suggest that it may be 
effective for even longer [20]. In a study assessing the effectiveness of the TCu380A IUD 
over 10 years of use, the authors observed no pregnancies in 366 woman-years of 
observation. Furthermore, the study found that the IUD did not lose its effectiveness after 
10 years of use [21]. 
 
Barriers to promoting the IUD in sub-Saharan Africa 
There are various barriers which have inhibited the wide-spread use of the IUD in sub-
Saharan Africa. Barriers such as safety concerns, myths regarding the IUD and provider 
training are often reported as factors that continue to limit the use of the IUD in 
developing countries. 
 
Risk of Pelvic Inflammatory Disease (PID) 
One of the barriers to IUD use among women is the belief that it can cause PID. Earlier 
research suggested this causal association, but it has since been disproved [22]. Previous 
designs of the IUD, most notably the Dalkon Shield, contained multifilament strings 
which were implicated in the higher rates of PID see among IUD users [23]. The copper 
T IUD, on the other hand, does not have braided strings and therefore there is no 













PID occurs when pathogenic microorganisms come up from the cervix and enter the 
endometrium and the fallopian tubes, causing an inflammatory response [24]. PID can 
also be caused by the presence of sexually transmitted infections (STIs), most notably 
chlamydia and gonorrhoea [25]. Therefore, there are concerns that women with a STI, 
who are already at increased risk for PID will further increase their risk of developing 
PID with the insertion of an IUD which could transport already present sexually 
transmitted microorganisms from the endocervical canal into the uterine cavity [26]. 
However, some studies have shown that STI prevalence can be overestimated. A study 
conducted in the West African region found the prevalence of chlamydia and gonorrhoea 
to be much lower than the reported range of some East and Southern African countries. 
This perception that clients were at high risk for PID because of STIs has left some 
family planning programs under-providing the IUD because of incorrect beliefs [27]. 
Studies have shown that users are most at risk of PID 20 days after IUD insertion [28]. A 
study found that in the early insertion period, the absolute risk of PID is approximately 
1% [29]. After the first 20 days, the risk of PID is quite small at 1.6 per 1000 women 
years, except in cases of an untreated STI [30]. 
While having a STI increases one’s risk of PID if using an IUD, there is little evidence 
that HIV infection increases that risk [28]. In a Kenyan study of IUD use among HIV 
positive and negative women, the incidence of PID was minimal in both groups with 
rates of 1.4% in HIV infected women compared to 0.2% in non-infected women. The 
difference was not statistically significant between HIV-positive and negative women 
[31]. Another Kenyan study had a similar finding with PID rates of 2.0% in HIV positive 












Rumors and Myths about the IUD 
One of the most pervasive reasons for low level IUD use is the clients’ lack of knowledge 
about the method. Many women are unaware of the method or lack knowledge about the 
effectiveness, benefits, side effects and costs of the IUD. Women also hear many myths 
and rumors about the IUD which might dissuade them from using it. 
Misconceptions and myths about the IUD are rampant in family planning settings around 
the world. Not only do clients hold incorrect beliefs about the IUD, but providers do as 
well. One common myth is that the IUD can move around to other parts of the body from 
the uterus [33-34]. Another rumour is you can become pregnant using the IUD and the 
baby will be born with the IUD embedded in its body [33, 35]. The IUD has also been 
associated with causing cancer, but there is no evidence to suggest this is true. It is also a 
common belief that the IUD can fall out easily or become expelled easily [33]. Some 
believe that the IUD can become lodged in the cervix, uterus or penis [35]. Another 
common misconception is that the IUD can cause abortions by preventing implantation of 
the embryo [33, 36]. This belief has prevented many women from getting an IUD and 
providers from suggesting the method. A common myth among providers is that the IUD 
increases the risk of a  ectopic pregnancy. However, the IUD is so effective that women 
using it are actually at a decreased risk compared to women using no contraception [36]. 
While women who don’t use the IUD tend to view the method negatively, users of the 
method often report satisfaction with the method [33]. Furthermore, providers can play an 
important role in dispelling myths and rumors about the IUD in order to increase its 














Health System Barriers 
In many developing countries, providers often lack the skills, training and resources 
needed to insert IUDs. If the IUD is to be promoted and used by more women, obstacles 
in the health system must be addressed. Some barriers include postponed initiation of 
contraception, incorrect contraindications, misinformation, and the accessibility and cost 
of contraceptive methods [37].  
A study in Zambia found that barriers to IUD use included lack of demand or interest on 
the part of users, lack of skilled and trained providers, lack of a consistent supply of 
materials and equipment and possible health worker bias in that providers may favor 
short-acting methods which are quicker to provide [38]. These service delivery 
challenges may influence whether a provider even discusses the IUD with a client [39]. 
Providers can also be misinformed about who is eligible to use the IUD, believing that it 
is contraindicated for nulliparous and HIV positive women [8]. Moreover, a recurring 
belief that the IUD can lead to infection further limits its use as well as worries of 
litigation due to incorrect insertion [39].  
Provider limitations are another barrier in providing the IUD to women. These barriers 
include lack of knowledge or comfort with different types of contraception, lack of 
experience with various methods and little to no time to discuss or counsel patients about 
certain methods [40]. There is also a lack of equipment to train providers to insert the 
IUD as well as a lack of trainers to teach the skills to other providers. Furthermore, many 
providers lack confidence in their skills, which suggests that in order for them to maintain 












that while they are trained to insert IUDs, they do not have enough practical experience 
doing so [33]. There is also a lack of knowledge among providers. For instance, some 
providers did not know that the IUD was not to be inserted in the presence of a STI or 
they did not know the length of use for the IUD. There are also programmatic barriers in 
that in many cases only doctors and nurses can insert the IUD. This leaves out auxiliary 
and paramedical providers from providing the method. Also in some instances, the IUD 
is only offered during the six-week postpartum period and not to other postpartum or 
post-abortion clients [41]. 
 
Interventions to promote the IUD in sub-Saharan Africa 
There have been various interventions throughout sub-Saharan Africa to try and increase 
uptake of the IUD among women. I evaluated the effect of a selection of interventions to 
increase uptake of the copper IUD. I included one randomised trial and four before and 
after studies of interventions, which measured use and uptake of the copper IUD as an 
outcome.  Largely, the studies included in this review could be divided into two types of 
interventions: interventions using a “supply-demand-advocacy” model and community-
based contraceptive counselling. Table 1 summarises the included studies. 
 
Supply-Demand-Advocacy Interventions 
Three studies reported the impact of the Supply-Demand-Advocacy model on the uptake 
of the IUD. The term “supply and demand” refers to a mixture of interventions that 
include provider training, the provision of high standard products and the development of 












inform relevant parties and potential clients about the IUD, its effectiveness, benefits, 
side effects and where to find IUD services. Advocacy refers to involving vital 
stakeholders in supporting IUD efforts. An increase in IUD uptake was observed in all 
three studies. In a project done in the Kisii District, Nyanza Province of western Kenya 
among 13 service sites, IUD insertions rose from 58 at the start of the intervention to 484 
at the end of the two-year intervention period. Prior to the intervention, only 0.5% of 
women used the IUD. Furthermore, a year after the intervention ended, IUD insertions 
rates were still high at 453 insertions [42]. Another project done in the Amhara region of 
Ethiopia over three hospitals and ten health centers saw IUD insertions go from 182, the 
highest they had ever been before the intervention, to 338 over a nine-month period of the 
intervention taking place [43]. Prior to the intervention taking place, only 0.2% of women 
used the IUD. Lastly, a project done in the Suguiri District of Guinea at the provincial 
hospital and six health centers saw an increase of 37 IUD clients in the two years before 












Table 1: Selection of studies reporting on IUD interventions in sub-Saharan Africa 
Author Year Setting Design Intervention 
Taylor 
43 
2008 Ethiopia Before and 
after 
Approximately 780 community-based reproductive health agents across three hospitals 
and ten health centres were trained to include the IUD in their family planning services. 
The training included an upgrade in provider’s clinical skills as well as improving 
safety and infection control protocol. A communications campaign was also launched, 
which included radio ads, billboards and posters. To support health facilities offering 
IUD services, door signs, leaflets and technical booklets on the IUD were made. 
Taylor 
42 
2008 Kenya Before and 
after 
A performance assessment was conducted at 13 service sites in the Kisii District. 
Training was provided to improve technical skills in inserting and removing the IUD as 
well as counselling skills. In addition, two providers from each site were selected to 
train and manage community-based distribution agents for referrals. Furthermore, all 13 
sites were equipped with two IUD kits and sterilization equipment if necessary. The 
programme also included communications activities, which produced advertisements, 
radio spots, a weekly talk show and print materials to educate and inform potential 




2008 Guinea Before and 
after 
IUD services at 13 sites were upgraded by providing training on IUD insertion and 
removal, improving counselling skills and infection control. Trained health care 
providers were encouraged to share their newly acquired skills with others in order to 
increase IUD knowledge and skills among other providers. Using mass media such as 
radio and various print materials such as brochures and posters an IUD demand 
campaign was created. The programme also held meetings with key stakeholders in 





2008 Kenya Randomised 
trial 
This intervention tested the use of an outreach intervention called ‘detailing’ to family 
planning providers and community-based distribution (CBD) agents to promote the 
IUD. ‘Detailing’ was explained as having a role model visit various facilities that 
provide family planning to “educate, motivate, and facilitate” a particular outcome, 












was trained as a ‘detailer’. Detailers visited family planning providers and CBD agents 
twice to educate and motivate them about the IUD. The study sites were 45 public 
sector rural health facilities in 5 districts that currently had family planning 
programmes. The detailers held group discussions with the family planning providers 
and CBD agents to discuss issues related to the IUD such as barriers to its use, 
effectiveness and side effects as well as myths and rumors about the method. Detailers 
also gave providers and agents educational pamphlets about family planning and the 
IUD as well as promotional products. The health clinics were randomised to receive the 





2011 Zambia Before and 
after 
18 midwives were employed and trained to be dedicated providers of long-acting 
reversible contraception (LARC). The midwives spent their time at existing public 
sector clinics providing and promoting LARC to clients. Their work supplemented that 
of the current staff by increasing the length of time that LARC was available as 
educating the existing staff about LARC. The midwives conducted talks on LARC to 
women waiting in the clinic waiting rooms, offering same day services if needed. Two 
LARC options were provided to clients: a subdermal levonorgestrel implant or the 
Copper T IUD. The women did not pay for services, were told to return for removal at 
any time and were given a card with information about the LARC option they chose. 
Furthermore, the midwives used comments from new clients to educate other women 















Community-based contraceptive counselling 
Two studies evaluated the impact of contraceptive counselling by trained community workers 
on the uptake of the IUD. A greater increase in the uptake of the IUD was observed in the 
Zambian than in the Kenyan study. In the Zambian study, 287 clients received either an IUD 
or an implant at baseline. After 14 months of the intervention, 33,609 women had chosen to 
use LARC with 22,079 choosing the implant and 11,530 choosing the IUD [38]. In the 
Kenyan randomised trial, there was a small increase in IUD uptake in one arm of the 
intervention, but not in the other two [45]. The study found that IUD promotion by both CBD 
agents and providers made a small increase in IUD uptake compared to no promotion. IUD 
promotion by only CBD agents or providers did not produce a similar outcome. 
 
IUD Use for HIV positive women 
An estimated 23.5 million people in sub-Saharan Africa have HIV, with women accounting 
for nearly 58% of them [46]. In studies of HIV positive women, nearly 70% were sexually 
active with variable use of contraception and numerous reports of unplanned pregnancies 
[30]. Various studies have suggested that systemic hormonal contraception use may increase 
HIV transmission from HIV positive females to their male partners and quicken HIV 
progression among users [47,48,49,50,51]. Furthermore, this concern has particularly focused 
on those who use DMPA which is very popular in Southern Africa. These findings have only 
highlighted the need for safe and effective long-acting reversible contraceptive methods for 
HIV infected women. 
Recent evidence suggests that IUDs are safe for use in HIV positive women. Two cohort 
studies in Kenya both found low overall complication rates following insertion of the IUD in 












HIV positive women and 14.8% of HIV negative women, while in the second study it was 
7.6% of HIV positive women and 7.9% of HIV negative women. Both studies conclude that 
HIV does not appear to increase the risk of IUD-related complications. [31-32]. Another 
study found that the IUD use does not increase cervical shedding of HIV, thus it does not 
seem to increase the risk of transmission to an HIV negative partner [52].  This evidence 
spurred the WHO to change its guidelines for IUD use among HIV positive women [53]. 
Previously, guidelines put IUD use by HIV positive women in Category 3 which states “A 
condition where the theoretical or proven risks usually outweigh the advantages of using the 
method.” Now it has been moved to Category 2 which describes “A condition where the 
advantages of using the method generally outweigh the theoretical or proven risks [54].” In 
addition, a randomised control trial done in Zambia among HIV positive women found that 
women who took hormonal contraception were more likely to become pregnant than women 
who used the IUD. Moreover, clinical disease progression was more likely to occur among 
those using hormonal contraception than those using the IUD [55]. 
Further studies have found that not only is the IUD a beneficial contraceptive method, it is 
one that HIV positive women are interested in using. A cross-sectional survey done in South 
Africa found that 86% of women interviewed were interested in future IUD use even though 
only 37% of women were aware of the method [56]. Another cross-sectional study done in 
South Africa found that a significantly greater proportion of HIV positive women found the 
IUD favourable than HIV negative clients (79.3% vs.68.9%, p=.001). Women from both 
groups were interested in the IUD despite very few of them being told about the method by a 
provider (7.8% vs. 10.0%). More than half of the participants (both HIV positive and 
negative) lacked knowledge about the effectiveness of the IUD, eligibility for IUD use and 
side effects of using the IUD [57]. Most of women were using injectable contraceptives, 












lack of knowledge that women have about LAPMs may also be prohibiting them from using 
them. These studies suggests that even with low levels of IUD awareness, HIV positive 
women still display an interest in using the IUD. 
 
Investing in LAPMs in sub-Saharan Africa 
There is a recognized gap between the need for LAPMs in developing countries and the 
provision of LAPM services. Particularly in sub-Saharan Africa, LAPMs are still a missing 
component of many family planning programmes. If barriers to their availability can be 
surpassed, LAPMs can augment family planning services in many important ways.  
As stated previously, there is a high unmet need for contraception in sub-Saharan Africa. An 
estimated 25% of women and couples in sub-Saharan Africa who wish to space their 
childbearing or limit their births are not using any contraceptive method [58].  The reasons to 
invest in LAPM are undeniable.  In sub-Saharan Africa alone, there are approximately 14 
million unintended pregnancies every year, mostly due to the use and failure of short-term 
contraceptive methods like the oral contraceptive or injectable [1]. When women use family 
planning options like LAPMs to space and limit their pregnancies, unintended pregnancy 
rates will decrease.  
IUDs especially are one of the most cost-effective contraceptive methods on the market. A 
study that did an economic analysis of contraceptives for women found that the least costly 
methods were the hormonal IUD and the copper T IUD [17]. While the total cost of an actual 
IUD is high, its initial costs amortize over time as it a long-term contraceptive method with a 
very high effectiveness rate [17]. Another economic analysis study found that while having 
high initial costs, LARC methods were more cost-effective than combined oral 
contraceptives. They also prevented more unintended pregnancies and resulted in net-cost 












analysis study found switching from progestin injectables to the copper T IUD would lower 
incident HIV diagnoses while maintaining or increasing life expectancy [60]. 
LAPMs are a highly beneficial option for women who want to delay childbearing, space 
births or have decided that they do not desire any more children. While many misconceptions 
abound about who can and cannot use LAPMs almost all women are eligible. LAPMs can be 
used by adolescents and older women, nulliparous women and those who have had children 
and by HIV positive women. One of the major advantages of LAPMs is that they require 
little maintenance once initiated. They do not require ongoing resupply, thus putting less of a 
burden on the health system.  
The use of LAPMs in sub-Saharan Africa is low. Of those who are using contraception, fewer 
than 5% are using a LAPM [54]. The IUD is particularly underutilized as very few users of 
contraception employ this method [8,61]. In some cases, the low use of LAPMs is due to 
limited access. As LAPMs are methods that can only be given by a health care provider, the 
health care system is the only entry point for accessing LAPM. The structure of the health 
system and the practices and perceptions of the provider can have influence over a client’s 
access to LAPM. Eligibility criteria which specify what kind of client can use LAPMs is also 
often a barrier to access as providers may deny LAPMs to clients based on old or incorrect 
restrictions. Furthermore, providers may not offer a client comprehensive information about 
the available contraceptive methods, leading the client to make an uninformed choice. 
While these challenges to providing LAPM exist, they certainly can be overcome. Providing 
women with comprehensive contraceptive choices is critical. Family planning is not only a 
human right, but a benefit to public health. Improving LAPM services will not only meet the 
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Background: The Copper T intrauterine device (IUD) is a safe and effective form of 
contraception that is not used widely in South Africa due to barriers such as lack of demand. 
This study tested the effectiveness of an intervention to increase the demand for IUDs. 
Study Design: A brief randomised counselling intervention was conducted among 110 
clients at 1 community health centre in Cape Town. 
Results: The mean age of participants was 30 years. Seventy-one percent of clients were HIV 
positive and 61% had used a modern contraceptive method in the past 12 months. Forty-six 
percent of clients had heard of the IUD and after being given a description of the IUD, 36% 
said they would consider using it. Only 16% of clients had a health care provider discuss the 
IUD with them and before the interview, 27% said they would be interested in receiving an 
IUD that day. Five percent of the 56 women assigned to the control group went to family 
planning to make an appointment for IUD insertion, while 4% of the 54 women in the 
intervention group made an IUD insertion appointment (p=.68). No participants had the IUD 
inserted over the 1-month follow-up period. 
Conclusions: These data suggest that counselling alone is not enough to increase IUD 
uptake. These study results suggest that a more intensive intervention is needed to see an 























The Copper T intrauterine device is one of the most popular methods of contraception around 
the world. It protects over 100 million women and comes only second in popularity to 
sterilisation [1-2]. The IUD is one of the most effective forms of contraception, offering 
protection against pregnancy for up to 10 years, with a less than 1% of risk of pregnancy 
during the first year of use [3]. The IUD is beneficial for many reasons among which is that it 
does not require multiple visits to a health care provider, requires little to no care on the part 
of the woman and can provide short-term protection for women who wish to space their 
childbearing. Furthermore, it is a long acting reversible contraceptive method, making it ideal 
for women who are not ready for a more permanent option such as sterilisation [4]. 
Even though among sub-Saharan countries South Africa has the highest use of contraception, 
the IUD continues to be the least chosen method [5]. Globally, South Africa is one of the 
countries with the lowest levels of usage, with reports of less than 1% of women using the 
IUD [4,6]. In Cape Town, two previous studies have shown levels of IUD use to be at 5% 
and 0% correspondingly [7]. IUD promotion is especially important in light of the new South 
African National Contraception Policy and Guidelines. The new guidelines include the 
expansion of contraceptive choice and the reintroduction of available, but underutilised 
methods such as the IUD [8]. 
Pervasive rumors and myths about the IUD, safety concerns and a lack of trained providers 
are just some of the barriers that continue to hinder IUD use in many developing countries 
[1,15] . Research suggests that the same barriers are commonly reported across different 
study populations and countries. Safety concerns about the IUD include the risk of 
developing pelvic inflammatory disease (PID) in both HIV-negative and positive women and 












in HIV-positve women include the risk of female-to-male HIV transmission [2]. Studies have 
shown that not only is the risk of PID minimal, but that the IUD is a safe and effective choice 
for HIV positive women [1-2, 9-13]. Myths about the IUD, such as it being able to travel 
throughout the body or become embedded in the uterus are another frequently cited barrier to 
IUD use [4, 14]. Lastly, lack of knowledge of the IUD if often mentioned as a hindrance to 
IUD uptake as many women remain unaware of the method [7].  
Despite these barriers, South African women have shown interest in the IUD. In a survey 
done in the Eastern and Western Cape, 89% of clients reported that they thought there was a 
benefit to the IUD and after being given a description of the IUD, 74% stated that they would 
consider using it [6]. While there has been a plethora of research done regarding barriers to 
IUD use, relatively little work has been done on IUD promotion. Furthermore, there is a lack 
of data on how to promote IUD use among the South African population. A Zambian study 
found that hiring dedicated providers of long-acting reversible contraception (LARC) 
significantly increased IUD uptake among women. Over a 14-month period, 33,069 women 
received LARC with 11,530 of those receiving the IUD [15]. A cohort study of Rwandan and 
Zambian women found that fertility-based counseling among HIV-discordant couples 
increased the use of LARC (IUD and implants) [16]. Of the 365 Rwandan women counseled, 
30 chose the IUD while of the 528 Zambian women counseled, 38 chose the IUD [16]. Other 
interventions to promote the IUD have had varied effect [17-19]. The varying successes and 
designs of these interventions make it difficult to determine what approach will work best. 
This study evaluated a brief counselling intervention in order to inform strategies for 















Materials and Methods 
A randomized controlled trial was conducted to test the impact of a counseling intervention 
on IUD uptake among 110 women attending a public clinic in Gugulethu, Cape Town. 
 
Setting 
A counselling intervention was conducted at the Gugulethu Community Health Centre 
located in the urban Nyanga district of Cape Town between November and December 2012. 
The district has an approximate population of 350,000 with the majority of people being 
unemployed and living in informal dwellings. The facility provides a range of primary health 
care services, including an antiretroviral therapy clinic and family planning [20]. The 
majority of clients attending the family planning clinic use the injectable, condom or oral 
contraceptive pill. At the time of the study, IUD services at the family planning clinic were 
available by appointment only. One provider runs the family planning clinic. 
 
Participants and Procedures 
Eligible participants were women between 18 and 45 years of age who were not pregnant, 
sterilised or currently using the IUD, were able to provide written informed consent and who 
did not currently desire childbearing (see Appendix A). Participants who were currently using 
contraception were eligible, including those with an unmet need for contraception.  
Participants were recruited from the waiting areas of the ARV clinic and family planning 
clinic. 
Convenience sampling was used to recruit women from the waiting room areas of the clinic. 
Potential clients were approached by study staff in clinic waiting rooms and asked for interest 
in study participation. Interested women were brought to a private room to further discuss the 
study and give written informed consent. Following consent, all participants were 












Following the questionnaire, all clients were given an educational pamphlet about the IUD in 
either English or isiXhosa and a study participant card. Participants were followed-up after 
one month. 
Consent to conduct the study was granted by the Research Ethics Committee of the Faculty 
of Health Sciences at the University of Cape Town (REC Reference 332/2012) and the 
Provincial Government of the Western Cape (RP 145/2012) which permitted access to the 
clinic (see Appendix E and F). 
 
Intervention 
Those randomised to the intervention group received an educational IUD pamphlet plus five 
to ten minutes of counselling regarding the IUD. The counselling included information about 
the effectiveness of the IUD as well the benefits, side effects and clarification of 
misconceptions or rumors about the device (see Appendix B). The counselling also included 
information about who could and could not use the IUD as well as information about the 
insertion procedure. Unlike the control group, clients in the intervention group were shown 
both the IUD and the insertion process during counselling and were allowed to touch the 
device. Furthermore, clients were able to ask questions about the device during counselling. 
The counselling was developed from current literature about the IUD as well as consultation 
with health care providers in the reproductive health field. The counselling was piloted before 
implementation. An experienced counsellor who underwent training about the IUD by the 
principal investigator administered the counselling. The counselling was administered in the 
participant’s preferred language, either isiXhosa or English. The staff giving the counselling 

















Those randomised to the control group received the current standard of care which is an 
educational IUD pamphlet. The pamphlet explained what the IUD is, benefits and side effects 
of using the IUD and the IUD’s effect on fertility (see Appendix C). 
 
Measures 
A questionnaire was administered to all clients in their preferred language by a trained 
interviewer after informed consent was given (see Appendix D). The questionnaire was 
piloted before use and assessed by the principal investigator for accuracy and completion. 
The study instrument assessed sociodemographic and economic information, reproductive 
health history, the client’s knowledge and attitude toward the IUD and health locus of 
control. Locus of control was considered as a potential predictor of future IUD use. Locus of 
control is a general construct which alludes to “the degree to which persons expect that a 
reinforcement or an outcome of their behavior is contingent on their own behavior or 
personal characteristics versus the degree to which persons expect that the reinforcement or 
outcome is a function of chance, luck, or fate, is under the control of powerful others, or is 
simply unpredictable” [21]. The Multidimensional Health Locus of Control scale was used to 
measure clients’ beliefs in their ability to control health outcomes or behaviors [22]. 
Participants were asked to rate how much they agree with a certain statement using a 6-point 
Likert scale. Two constructs were measured with the scale, internal health locus of control 
and chance health locus of control. Internal health locus of control measures how much 
control a client believes she has over her own health or health behaviors and chance locus of 
control measures how much a client believes her health is due to chance or fate. The analysis 
measured external locus of control with questions such as “If it’s meant to be, I will become 
pregnant” and internal locus of control with questions such as “I am in control of whether or 
not I become pregnant” , with responses ranging from strongly disagree to strongly agree. 












control and knowledge and use of contraception [23-24]. Participants were also asked to rate 
how much they agree with certain statements regarding contraceptive characteristics using a 
3-point likert scale. 
 
Randomisation 
For allocation of the participants, a computer-generated list of random numbers was used. 
The numbers were then put into opaque envelopes and sealed. Following the questionnaire, 




The primary outcome of interest was having an IUD inserted and the secondary outcome of 
interest was making an IUD insertion appointment. Participant follow-up happened after one 
month. IUD insertions were measured by review of daily family planning registers and folder 
review of family planning clients. IUD appointments were ascertained by looking at the IUD 
appointment diary kept by the family planning provider. 
  
Sample size 
To detect at least a 30% absolute increase in uptake of the IUD (between 30% and 60% for 
the control and intervention groups respectively) with a precision of 5% and 80% power, a 
sample size of 100 participants was necessary. Prior research which conducted an 
intervention at the community level reported an absolute increase of approximately 25%.[19] 
















All data were entered into Microsoft Excel and double data entry was performed. Data were 
analysed using Stata 10 (Stata, College Station, TX, USA). Descriptive statistics were 
calculated for select demographic and reproductive health characteristics and were compared 
between the control and intervention groups. The significance of any differences between 
these two groups was assessed by chi-square and t-tests. Bivariate associations between 
participant characteristics and these variables were described using t-tests for means and chi-
square tests or Fisher’s exact test for proportions as appropriate. Select demographic and 
reproductive health variables were used to assess significant bivariate relationships with 
being aware of the IUD, having made an IUD appointment and locus of control. The number 




Between November and December 2012, 110 women participated in the trial. Of the 110 
women, a total of 56 were assigned randomly to the control arm while 54 were assigned to 
the intervention arm (Figure 1). There were no losses or exclusions after randomisation.  
 



















intervention (n= 54) 
♦ Received allocated 
intervention (n= 54) 
Achieved 1 month 
follow-up (n= 54) 
Allocated to control 
(n= 56) 
♦ Received allocated 
intervention (n= 56) 
Achieved 1 month 



















The mean age of participants was 30 years. Participants were slightly older in the control 
group (mean: 30.7 years) than in the intervention group (mean: 29.8 years) (Table 1). The 
median years of education were 11 years. The majority of participants were unemployed (62 
%) and almost all participants (91%) spoke isiXhosa as their primary language. Nearly half of 
the participants (45%) lived in an informal dwelling or shack. The mean gravidity was 1.8 
(Table 1). Women in the control group had a higher mean number of pregnancies (1.9) than 
women in the intervention group (1.6). Over half the participants (58%) had experienced an 
unwanted pregnancy.  The majority of participants (71%) were HIV positive with over half 
(64%) taking antiretroviral therapy. Most women reported that they were currently in a sexual 
relationship (79%).  
Nearly half the participants (48%) had discussed family planning with their partner or 
husband, while the majority (61%) had used a modern contraceptive method in the past 12 
months (Table 1). The most commonly used methods were the male condom (56%), the 3-
month injectable (40%), the 2-month injectable (26%) and the oral contraceptive pill (6%) 
(Table 1). There were no significant differences between the intervention and control groups. 
 
Table 1: Sociodemographic, health, reproductive and contraceptive characteristics of clients 
Variable Total 
N = 110 
Control 
N = 56 
Intervention 
N = 54 
P-value 







Native language, n (%)    .86 
   IsiXhosa 100 
(90.9) 
 
52 (92.9) 48 (88.9) 
 
 







Median years of schooling (SD) 11 (2.0) 11 (1.5) 11 (2.4) .15 
Type of home, n (%)     













Mean gravidity (SD) 1.8 (1.3) 1.9 (1.3) 
 
1.6 (1.3) .19 
































Discussed family planning with 









Used modern contraceptive method in 









Type of method, n (%)     
   2- month injectable 28 (25.5) 14 (25.0) 14 (25.9) .91 
   3-month injectable 44 (40.0) 23 (41.1) 21 (38.9) .72 
   Oral contraceptive pill 6 (5.5) 4 (7.1) 2 (3.7) .64 
   Male condom 62 (56.4) 30 (53.6) 32 (59.3) .81 
 
Awareness and Attitude toward the IUD 
Approximately 46% of participants had ever heard of the IUD and after being given a brief 
description, 36% said they would consider using the IUD (Table 2). Twenty-one percent of 
participants knew someone who used an IUD, while only 16 % had ever had a health care 
provider discuss the IUD with them. Approximately a quarter of participants (27%) were 
interested in receiving an IUD that day. 
 
 
Table 2: Client awareness and attitude toward the IUD  
Variable Total 
N = 110 
Control 
N = 56 
Intervention 
N = 54 
P-value 







Would consider using the IUD, n (%)   
 
 .63 
   No 
   Yes 


















Health care provider has ever discussed IUD 








Interested in receiving an IUD today, n (%)    .61 
   No 
   Yes 
   Maybe 


























Health locus of control 
There were no significant differences at baseline between external and internal locus of 
control (Table 3).A,B 
Table 3: Perceived control of fertility 
Variable Total 
N = 110 
Control 
N = 56 
Intervention 
N = 54 
P-value 
Mean Internal Health Locus of Control 
(SD)  
30.0 (6.1) 29.4 (6.6) 30.6 (5.5) .30 
   It is my own behaviour which  
  determines when or if I become  
  pregnant  
4.4 (1.9) 4.2 (1.9) 4.6 (1.9) .34 
   I am in control of whether or not I  
   become pregnant 
4.8 (2.0) 4.9 (1.6) 4.6 (2.4) .41 
   If I become pregnant accidentally,  
   it is  my own fault 
4.8 (1.8) 4.7 (1.9) 4.9 (1.6) .57 
   Whether or not I become pregnant  
   depends on if I use contraception 
5.2 (1.4) 5.1 (1.4) 5.4 (1.4) .43 
   If I take contraception, I can avoid  
   becoming pregnant 
5.5 (1.4) 5.4 (1.4) 5.6 (1.3) .45 
   If I take contraception, I can  
   prevent pregnancy 
5.4 (1.7) 5.1 (2.1) 5.6 (.97) .08 
Mean External Health Locus of Control 
(SD) 
19.1 (7.1) 19.1 (7.6) 19.1 (6.6) .99 
   Often I feel like no matter what I 
   do, if I am going to become  
   pregnant, I will become pregnant 
3.3 (2.1) 3.3 (2.1) 3.2 (2.1) .77 
   It seems that whether or not I  
   become pregnant is great  
   influenced by chance 
3.3 (1.9) 3.3 (1.9) 3.3 (2.0) .83 
   When it comes to whether or not I  
   become pregnant, I just have to let 
   nature run its course 
2.5 (1.9) 2.8 (2.0) 2.3 (1.8) .18 
   Whether or not I become pregnant 
   is largely a matter of good fortune 
2.9 (1.9) 2.9 (1.9) 3.0 (2.0) .71 
   Even if I take contraception, it’s  
   easy to become pregnant 
4.5 (1.9) 4.4 (1.9) 4.6 (1.8) .45 
   If it’s meant to be, I will become  
   pregnant 
2.6 (2.0) 2.7 (2.0) 2.6 (2.1) .88 
 
Factors associated with awareness of the IUD 
Half of the women in the intervention group had heard of the IUD while 41% of those in the 
control group had heard of the IUD (Table 4). Older women were significantly more likely to 
know about the IUD (p=.002) as well as women with higher gravidity (p=.03). There were no 
significant differences in regards to unintended pregnancy, sexual relationship status and 
modern contraceptive use in the past 12 months between those who were aware and not 
                                                
A Strongly disagree indicates a rating of 1 on a scale of 1-6. 












aware of the IUD. 
 
Table 4: Characteristics associated with awareness of the IUD 
Variable Aware of IUD Not aware of IUD p-value 
Control, n (%) 23 (41.8) 32 (58.2) 
Intervention, n (%) 27 (50.0) 27 (50.0) 
.44 
Mean age in years (SD) 32.6 (7.2) 28.2 (6.9) .002 
Mean gravidity (SD) 2.1 (1.3) 1.6 (1.3) .03 
Previous pregnancy 
unintended, n (%) 
13 (54.2) 11 (45.8) .20 
Currently in a sexual 
relationship, n (%) 
37 (43.0) 49 (57.0) .25 
Used modern 
contraceptive method in 
the past 12 months, n (%) 
 
29 (43.3) 38 (56.7) .49 
 
Of the 56 women assigned to the control group, 3 (5%) made an appointment for IUD 
insertion while 2 (4%) of the 54 women assigned to the intervention group made an 
appointment (RR = .69, 95% CI: .12-3.98, p=.68) (Table 5).  Of the women who had not used 
contraception in the past 12 months, none of those in the intervention group made an IUD 
appointment, while 2 (9%) of those in the control group did. No clients completed the 
outcome of interest during the 1-month follow-up period. 
 
 
Table 5: Characteristics associated with making an IUD appointment 
Variable IUD 
appointment 
No IUD appointment p-value 
Control, n (%) 3 (5.4) 53 (94.6) 
Intervention, n (%) 2 (3.7) 52 (96.3) 
1.0 
Mean age in years (SD) 26.6 (4.7) 30.4 (7.4) .88 
Mean gravidity (SD) 1.6 (1.3) 1.8 (1.3) .71 
Previous pregnancy unintended, n 
(%) 
1 (20.0) 24 (22.9) 1.0 
Currently in a sexual relationship, 
n (%) 
4 (80.0) 83 (79.1) 1.0 
Used modern contraceptive 
method in the past 12 months, n 
(%) 
 
3 (60.0) 64 (61.0) 1.0 
Not used modern contraception in 
the past 12 months (Control), n 
(%) 
2 (8.7) 21 (91.3) .49 
Not used modern contraception in 
the past 12 months (Intervention), 
n (%) 
0 (0.0) 20 (100.0)  
Ever heard of the IUD, n (%) 4 (80.0) 46 (44.2) .22 













Health care provider has ever 
discussed IUD with client, n (%) 
2 (40.0) 15 (14.3) .17 
Interested in receiving an IUD 
today, n (%) 
2 (40.0) 28 (26.7) .85 
Contraceptive characteristics 
which are important to 
participants, Mean (SD) 
   
   Effective at preventing    
   pregnancy 
3.0 (0.0) 2.8 (.92) .70 
   Effective at preventing  
   HIV/STIs 
2.4 (.89) 2.4 (.87) .98 
   Undetectable by male partner 1.6 (.89) 1.9 (.89) .46 
   Not necessary to remember  
   daily or with sexual activity 
1.4 (.89) 2.3 (.84) .01 
   Last for a long time without  
   requiring a medical visit 
2.6 (.55) 2.6 (.71) .91 
   Does not require a medical  
   provider to receive 
1.8 (1.1) 2.2 (.91) .30 
   Is “natural”/does not contain 
   hormones 
1.4 (.89) 2.3 (.84) .02 
   Does not change menstrual  
   bleeding patterns 
2.4 (.89) 2.4 (.84) .96 
   Causes menses to stop 2.4 (.89) 2.2 (.89) .66 
   Does not cause weight- 
   related side-effects 
2.6 (.89) 2.4 (.84) .54 
   Does not interact with ART 3.0 (0.0) 2.8 (.54) .42 
   Does not cause mood  
   changes 
2.0 (1.0) 2.3 (.85) .34 
Contraceptive characteristics 
which are problematic for 
participants, Mean (SD) 
 
   
   No effect on preventing STIs 2.6 (.89) 2.2 (.93) .37 
   Male partner aware of  
   method 
1.0 (0.0) 1.24 (.96) .58 
   Must remember to use at  
   every sex act or take daily 
1.8 (.92) 1.9 (.91) .89 
   Requires an injection 1.6 (.89) 1.6 (.82) .90 
   Requires a physician/medical 
   provider to provide 
1.6 (.89) 1.8 (.91) .65 
   Lasts for months or longer 1.0 (0.0) 1.4 (.75) .26 
   May interact with HIV  
   infection or ART 
3.0 (0.0) 2.6 (.75) .25 
   Causes irregular menstrual  
   bleeding 
3.0 (0.0) 2.5 (.76) .14 
   Causes menstrual bleeding to 
   stop 
2.0 (1.0) 2.3 (.87) .49 
   May cause mood changes 2.6 (.55) 2.3 (1.1) .56 
 
After being read a list of contraceptive characteristics, women were asked to rate their 
importance using a 3-point Likert scale. Women who reported that it was somewhat 
important for a contraceptive method to "not be necessary to remember daily or with sexual 












who rated "is natural/does not contain hormones" as somewhat important were also more 
likely to not make an IUD appointment (p=.02) (Table 5). Furthermore, women who 
moderately agreed with the statement "It seems that whether or not I become pregnant is 
greatly influenced by chance" were more likely to make an IUD appointment (p=.03) (Table 
6).  
Table 6:  Fertility characteristics associated with making an IUD appointment 
Variable IUD 
appointment 
No IUD appointment p-value 
Mean Internal Health Locus of 
Control (SD)  
33.0 (2.0) 29.9 (6.2) .27 
   It is my own behaviour which  
   determines when or if I become 
   pregnant  
4.4 (2.1) 4.4 (1.9) .99 
   I am in control of whether or   
   not I become pregnant 
5.8 (.45) 4.7 (2.0) .24 
   If I become pregnant  
   accidentally,  it is  my own  
   fault 
5.0 (2.2) 4.8 (1.8) .79 
   Whether or not I become  
   pregnant depends on if I use  
   contraception 
6.0 (0.0) 5.2 (1.4) .22 
   If I take contraception, I can  
   avoid  becoming pregnant 
5.8 (.45) 5.5 (1.4) .61 
   If I take contraception, I can  
   prevent pregnancy 
6.0 (0.0) 5.3 (1.7) .38 
Mean External Health Locus of 
Control (SD) 
18.2 (5.1) 19.2 (7.2) .77 
   Often I feel like no matter what 
   I do, if I am going to become  
   pregnant, I will become  
   pregnant 
3.0 (2.7) 3.3(2.1) .76 
   It seems that whether or not I  
   become pregnant is greatly  
   influenced by chance 
5.2 (1.8) 3.2 (1.9) .03 
   When it comes to whether or  
   not I become pregnant, I just  
   have to let nature run its course 
1.4 (.89) 2.6 (1.9) .18 
   Whether or not I become  
   pregnant is largely a matter of 
   good fortune 
2.2 (1.8) 3.0 (2.0) .38 
   Even if I take contraception,  
   it’s easy to become pregnant 
4.4 (2.3) 4.5 (1.9) .90 
   If it’s meant to be, I will  
   become  pregnant 
2.0 (1.4) 2.7 (2.1) .47 
 
Discussion 
This is one of the first studies to test the effect of a brief counselling intervention to increase 












IUD uptake was lower than expected. The number of IUD insertion appointments made was 
low in both the intervention and control groups.  In addition, the IUD was a relatively 
unknown method among the participants. Few participants had ever discussed the IUD with a 
health care provider or knew someone who used the IUD. The results of this study suggest 
that a brief counselling intervention may not be sufficient to increase the demand for the IUD.  
 
After counselling, no participants from either the control or intervention group had the IUD 
inserted. These results are similar to those of another study done in Cape Town [25]. 
Although women said they found discussing the IUD to be informative, it did not make any 
difference in the level of IUD uptake post-intervention.  It was recognized at the start of the 
study that it may be hard to show an effect on contraceptive use among the women as the 
study took place in the Western Cape, which has the second highest rate of contraceptive use 
among the provinces in South Africa [26]. Among the participants, a high percentage of 
women in both the intervention (59%) and control (63%) groups had used a modern method 
of contraception in the past 12 months. As some of the women may have been currently using 
a method, counselling may not have been enough of a motivation for them to switch to the 
IUD. Furthermore, while only 60% of women in both groups were using contraception, 80% 
of them were in sexual relationships. The 20% of women with unmet need could be described 
as less intentional or as having a more ambivalent feeling towards pregnancy [27]. A recent 
survey study found that women who less intentional about pregnancy or “okay either way” 
were often not taking contraception or not taking it on a regular basis [27]. 
Approximately half the participants in our study were aware of the IUD. This is more than 
the level found by the 2003 SADHS which stated that 39.7% of women were aware of the 
IUD [28]. Older women were more likely to be aware of the IUD before the start of the study. 












where the older cohort of women was more likely to know about the IUD [29]. This may be 
because over time they have been exposed to more contraceptive options than their younger 
peers. Women with higher gravidity were also more likely to be aware of the IUD.  This may 
possibly be because women in Cape Town are seen postpartum and then referred to family 
planning after each delivery, therefore they may have been counselled more extensively 
about contraception [25]. This may also be due to the fact that IUD is generally offered to 
women who have had children. Only a third of participants reported that they would consider 
using the method. This could be due to misconceptions and rumours that clients have heard 
about the IUD, similar to clients in studies from Ghana and El Salvador [4,14]. However, 
despite low levels of awareness, after being given a description of the IUD women were 
receptive to using the method, which is similar to findings in other South African studies [6-
7]. 
 
Approximately a quarter of participants stated that they would be interested in receiving an 
IUD that day. These results suggest that the IUD is an acceptable method of contraception for 
some of the women who were sampled. However, acceptability of a method does not always 
directly translate to use as evidenced in this study. When it comes to contraceptive decision 
making, a woman’s choice is likely influenced by a variety of factors which include health 
care provider recommendations, family recommendations and cost [30-31].  It can also be 
influenced by previous method use and the desire for a method which one can start 
immediately [32].  Lastly, one’s social network and partnership status can also have an 
impact on contraceptive choice [33-34]. This indicates that for a woman, choosing a 
contraceptive method is a complex decision that goes beyond liking a particular option. The 
affirmative responses we received in response to IUD usage may not be an accurate 














This study had several limitations. The study was underpowered as it had a small sample size 
of only 110 participants. The results suggest that our estimation was incorrect and we should 
have chosen a smaller effect size, thus giving us a larger sample size. The results may not be 
generalizable to all South African women of reproductive age because participants were 
enrolled through convenience sampling at one public sector Cape Town clinic. However, 
those women recruited from the family planning clinic could potentially become users of the 
IUD because they by definition are sexually active and seeking contraception. Our 
questionnaire also did not explore any negative or positive perceptions that the women had 
about the IUD. Qualitative research is needed to better understand women’s feeling about the 
method. In addition, no health care providers were interviewed during the intervention and no 
data was collected on the number of women who declined to participate and the reasons for 
refusal. At the time of the study, the family planning sister was not certified to insert IUDs 
alone and needed to be supervised by a trained superior. This may have served as a hindrance 
for clients as they would have to make two visits to have the IUD inserted. Having to make 
two visits for IUD insertion has been shown to be a barrier in increasing IUD use [35]. As the 
IUD was not made immediately available, its used may have been curtailed as evidenced by 
the thirty women willing to receive an IUD on the day of the intervention versus the five who 
actually made an appointment. Furthermore, the short duration of the study may have also not 
given women enough time to switch from their current contraception to the IUD. While data 
was collected on contraception use in the past 12 months, no data was collected on current 
contraceptive use which may have explained why IUD uptake was low. The literature also 
suggests that motivations for switching from one method to another may be different from 












A study of oral contraception discontinuation and switching in developing countries found 
that, on average, 35% of women switched to another method due to dissatisfaction within a 
three month period [37]. 
The short duration of the intervention may also have been a reason for low IUD uptake. Of 
the five women who made an IUD appointment, none of them returned for insertion. A 
retrospective review study showed that the median time between order and insertion was 43 
days, with actual time ranging from 1 to 392 days [35]. Furthermore, we did not know the 
distance that participants lived from the clinic and the same study showed that women who 
lived further from the clinic were less likely to return for IUD insertion [35]. 
Another limitation is we were not able to determine the reason for the IUD not being inserted. 
It’s possible the women changed their decision, chose another contraceptive method or went 
to another clinic to receive services. 
Recommendations 
Interventions that are low cost and can be integrated into the existing family planning 
programme should be attempted. The involvement of relevant stakeholders such as 
government officials, health care providers and community leaders early on in the process of 
implementing an intervention is crucial. They can help to identify the particular needs of a 
community and guarantee that interventions are targeted accordingly. At the time of the 
intervention, only one provider was available to insert IUDs. A more successful intervention 
might involve multiple providers who are trained to counsel women about the IUD as well as 
do insertions. Furthermore, an effective intervention would involve the development of 
Information, Education and Communication (IEC) materials, which would include print 
materials and other media such as radio and television.  
Evaluating community attitudes and barriers that hinder the use of LARC is important if a 












accomplished by in-depth studies or small focus group discussions that can provide insight 
into community beliefs and attitudes.  Piloting campaign materials will help show which 
messages are most appropriate and welcomed by both stakeholders and the community. 
Pretesting materials can also garner invaluable insights from members of the target audience.  
 
Conclusion 
The IUD is a safe and highly effective form of contraception, but is one of the least known 
methods among potential clients and one of the least counselled methods among providers in 
the study. The data suggest that simply being counselled about the IUD is not enough to 
increase uptake and that a more comprehensive and intensive campaign is needed in order to 
see an increase in IUD use. Future initiatives must focus on increasing women’s awareness 
about the method as well as the number of providers trained to insert the IUD. Programs 
should introduce the IUD as a contraceptive option in a variety of situations such as during 
the postpartum period or after a miscarriage or abortion. Providers’ ability to promote and 
deliver a range of contraceptive options must be strengthened if the IUD is to be used by 
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Purpose of research 
We are from the School of Public Health at the University of Cape Town. We are collecting 
information about family planning needs of women attending the Gugulethu Community Health Centre 
and specifically, whether they would be interested in using the intrauterine device (IUD/loop). This 
research is being done as part of a Master in Public Health degree at the University of Cape Town 
and is not part of clinical care.  
 
Your participation in this study is voluntary. Whether or not you decide to participate in this study will 
not affect your right to, or experience of treatment and care at this or any other clinic now or in the 
future. 
 
If you decide to participate: 
 This will involve you answering questions put to you by the interviewer, for about 30 
minutes. 
 
 You will be randomised to receive either an educational pamphlet about the IUD or the 
educational pamphlet and 5 -10 minutes of one-on-one counselling about the IUD.  
Randomisation means the selection of the IUD will be by chance, like tossing a coin or 
rolling dice.  
 
 All of the information that you provide will be kept completely private and confidential 
and will only be viewed and used by the researchers on this project. We will write down 
your name, but it will not be used in any published materials. Health care providers and 
other people at this clinic will not see this information. 
 
 You give researchers permission to access your health care records. 
 
 You have the right to decide not to participate in the study. If you do participate, you 
have the right to refuse to answer any specific questions, or to end the interview at any 
time without penalty.  
 
 The information you provide may help us to improve family planning services for 
women in the Cape Town area.  
 
Risks and Benefits 
Your participation in this study will not involve any risks to you. However, if you choose to undergo 
IUD insertion, you may experience side effects such as physical discomfort and/or changes in your 
menstrual cycle. You will receive information on family planning and contraception as a direct benefit 
for participating in this study. You will not receive any remuneration for taking part in this study. 
 
What happens at the end of the study? 
At the end of the study we will analyse the data collected from all the study participants. Information 
that we collected from you will be compared to others who took part in the study. The results will be 
published for a dissertation and may be reported in scientific journals. We also may wish to contact 
you in the future to discuss your participation in this study. Please initial below if you give permission 
for future contact. 
 















If there is anything that is unclear or if you need further information, please ask us and we will provide 
it. Do you have any questions? 
 
Additional Information 





School of Public Health and Family Medicine,  
Faculty of Health Sciences, 
University of Cape Town (UCT) 
Tel: +27 21 444 2758  
Email: Phumelele.Trasada@uct.ac.za 
 
If you have any questions about your rights as a study participant, you should contact: 
 
Professor Marc Blockman 
Chairperson, FHS Human Ethics 
Department of Medicine 
University of Cape Town (UCT) 
Tel: +27 21 406-6496 
Email: Marc.Blockman@uct.ac.za 
 
Participant volunteer declaration 
I have understood that the purpose of the study is to investigate family planning, and to understand 
specifically the interest of women in using the IUD in order to inform health care improvement.  
 
I have read the above information, or it has been read to me. I have had the opportunity to ask 
questions about it, and any questions that I have asked, have been answered to my satisfaction. I 
consent voluntarily to participate in this study and understand that I have the right to withdraw from 
the study at any time without in any way affecting my position as an attendee at this or any other clinic 
now or in the future. 
 








______________________________________________                              _ 
































Brief Intervention to promote IUD use 

















The Six-Step Counselling Model (GATHER) 
 
When introducing a client to a contraceptive method, client-centred 
counselling is one of the most effective ways to ensure successful and continuing 
contraceptive use. Your role as a counsellor is very important as the client is 
relying on you to give the correct information and may base their decision to use 
contraception on what you say. With that in mind, the six steps in the counselling 
process “GATHER”, should be taken into consideration. 
 
Greet: Greet the client in a friendly, helpful, and respectful manner 
Ask = Ask the client their name and if they have ever heard of the IUD or loop before 
today 
Tell = Tell client about the IUD/loop 
Help = Help client to understand the important facts about the IUD/loop  
Explain = Explain to the client how to use the IUD/loop 
Remind = Remind: Remind the client that if she wishes to have the IUD inserted or has 
any questions about contraception, she must make a follow-up visit to Family Planning.  
 
 
Counselling the Client 
 
1) Greet the client. Tell her your name and explain that you are going to spend the 
next 10 minutes telling her about the IUD or loop. 
2) Ask the client for her name and tell her that she can ask questions at any time. 
3) Tell the client what the IUD/loop is.  – “The IUD is a small, flexible, plastic and 
copper device placed in the womb. Most IUDs have 1 or 2 thin strings that hang 
from the cervix into the vagina (show client the IUD). The IUD provides 
protection against for pregnancy for 10-12 years. 
4) Next, Tell the client about the effectiveness of the IUD – “The IUD is a highly 
effective and safe form of contraception. In the first year of use, there are less 
than 6 pregnancies for every 1000 women. The only contraceptive more effective 
than the IUD is sterilisation. However, the IUD is reversible, unlike sterilisation 
which is a permanent method.” 
5) Tell the client how the IUD works – “The plastic and copper device prevents the 
sperm and the egg from meeting, therefore preventing pregnancy. This also 
means that the IUD does not cause abortions.” 
6) Tell the client that the IUD can be used for most women. This includes HIV 
positive women, with AIDS who are on ARVs (as long as they are well) and 
women who have never had children. Explain that the IUD cannot be used by 
women with the following: 
o Women with a current STI infection (Chlamydia or Gonorrhoea). 
The IUD can be inserted after the infection is treated 
o Women with unusual vaginal bleeding 
o Women who are pregnant – The sister will always check before 












o Women with genital or pelvic infections 
o Women with a high risk of STIs 
7) Help the client understand the important facts about the IUD – “Many women 
have a variety of concerns when deciding what method of family planning is best 
for them. Here are some important facts that you should know about the IUD: 
o Once the IUD is removed, your fertility will return immediately. In other 
words, you can start trying for a baby as soon as the IUD is taken out. 
o Using the IUD will not interfere with your sex drive or your mood.  
o Your partner cannot feel the IUD during sex. This is because it is 
inserted very high into the womb. 
o The IUD does not contain any medication or hormones. 
o Because the IUD does not contain any hormones, it will not cause weight 
gain or loss, a bloated or distended stomach or sore breasts. 
o Once the IUD is inserted, you do not have to do anything else. Unlike the 
pill or injectable, you don’t have to come back to the clinic every 2 or 3 
months.  
o The IUD CANNOT move around in the body. It cannot move into the 
heart, brain or throat. This is because the womb only has one opening 
which is through the vagina. 
8) Explain the side effects of the IUD – “Sometimes the IUD can cause side effects. 
You may experience longer or heavier periods and you may have more cramps 
during your period. Remember, not all women experience these side effects and 
they usually go away after the first few months.” 
9) Explain how the IUD is inserted – “The IUD will be inserted by a trained nurse in 
family planning.  It takes about 10 to 15 minutes. I am going to explain the IUD 
insertion process to you now: 
o First, the sister will give you some Brufren to help make the 
insertion less sore. This is not an operation, so you do not need an 
anesthetic. 
o Next, the sister will use an instrument called a speculum to open 
the vagina. She will look in your vagina to make sure everything 
looks healthy. 
o Then the sister will insert the IUD into the womb. You may feel 
some cramping or discomfort during this part. (Insert the IUD into 
the uterine model and show the client how the IUD looks once 
inserted) 
o After the IUD is inserted, the sister will cut the strings leaving 
about 3 cm hanging outside of the cervix 
o Afterwards, the sister will give you the following information: The 
name and type of IUD that was inserted, the date of insertion and 
the date when you should have it removed and the date for your 
six week check up. 
o You will rest for a few minutes, but you may return to work or 
school afterwards. You do not need to take leave from work. 
10) Remind the client that the IUD does not protect against STIs or HIV, so 
she must use a condom during sex. Also tell her that if she does not get her 
period, she should return to family planning for a pregnancy test. 
11) Remind the client that if she wishes to have the IUD inserted, she must 














Common Myths and Rumors about the IUD 
 
Rumors are unconfirmed stories that are transferred from one person to another by 
word of mouth while a misconception is a mistaken interpretation of ideas or 
information. If a misconception is imbued with elaborate details and becomes a 
fanciful story, then it acquires the characteristics of a rumor.  
 
Methods for Counteracting Rumors and Misinformation  
1. When a client mentions with a rumor, always listen politely. Don't laugh.  
2. Define what a rumor or misconception is.  
3. Find out where the rumor came from  
4. Explain the facts.  
5. Use strong scientific facts about family planning methods to counteract 
misinformation.  
6. Always tell the truth. Never try to hide side effects or problems that might occur 
with various methods.  
7. Clarify information with the use of demonstrations and visual aids.  
 
Rumor/Myth Facts 
The IUD might travel inside a 
woman's body to her heart or her 
brain.  
 
There is no opening from the womb to 
the other organs of the body. If the IUD is 
accidentally expelled or comes out, it 
comes out of the vagina, which is the 
only opening to the womb. 
The thread of the IUD can trap the 
penis during intercourse.  
 
The strings of the IUD are soft and 
flexible (let client feel the strings) and 
cling to the walls of the vagina and are 
rarely felt during intercourse. If the 
string is felt, it can be cut very short. The 
IUD cannot trap the penis, because it is 
located within the womb and the penis is 
positioned in the vagina during 
intercourse. 
A woman who was wearing an IUD 
became pregnant.  
The IUD became embedded in the 
baby's forehead.  
 
The baby is very well protected by the 
sac filled with amniotic fluid inside the 
mother's womb. If a woman gets 
pregnant with an IUD in place, the 
health provider should remove the 
IUD immediately due to the risk of 
infection. If for some reason the IUD is 
left in place during a pregnancy, it is 
usually expelled with the placenta or 
with the baby at birth.  
 












uterus after prolonged use the IUD can remain in place up to 10 
years. The IUD is made up of materials 
that cannot rust or rot; it simply loses its 









o Provides long-term protection against pregnancy for up to 10-12 years. 
o Is a small, flexible, plastic and copper device placed in the womb. Most IUDs have 
1 or 2 thin strings that hang from the cervix into the vagina. 
o A trained provider will insert and remove the IUD. 
o Safe for a woman with HIV or with AIDS who is clinically well on antiretroviral 
(ARV) therapy. 
o Not advised for a woman at very high risk of having a sexually transmitted 
infection (STI). 
o If you have a current STI (Chlamydia or Gonorrhoea) you must treated before an 
IUD can be inserted 
 
Effectiveness for pregnancy prevention: The pregnancy rate is: 
o In first year of use — less than 6 pregnancies per 1000 women 
o This is similar to female sterilisation, but the IUD is reversible 
 
 
How the method works: 
o The plastic and copper device helps prevent the sperm and egg from meeting. 




o Immediate return to fertility after IUD is removed 
o Does not interfere with sex drive 
o Your partner cannot feel the IUD during sex 
o Does not contain any medication or hormones 
o Will not cause weight gain/loss, fluid retention or breast tenderness 
o Does not require you to do anything once the IUD is inserted 
o The IUD CANNOT move around in the body 
 
 
Method not advised if you: 
o Are pregnant or think you might be pregnant. The sister will always check before 














o Have unusual vaginal bleeding. 




o Typically causes longer and heavier bleeding and more cramps or pain during 
monthly bleeding. 
o Side effects usually lessen after the first several months. 
 
Other benefits: 
o You will be offered a PAP smear if indicated 
o You will have a gynecological examination 
 
How to use (include demo): 
o The provider inserts the IUD into your uterus through your vagina and cervix 
o You do not need an anaesthetic. This is not an operation 
o The IUD is inserted in the clinic 
o You do not have to take leave from work 
o S/he cuts the strings on the IUD, leaving about 3 cm hanging out of the cervix 
o You will feel some discomfort or cramping during the procedure, this is 
normal.  
o After the procedure you will get the following information from your provider: 
– Type of IUD you have 
– Date of insertion 
– Date when IUD will need to be removed or replaced 
o You will be given a date for a check-up 6 weeks after insertion of the device 
 
REMEMBER: 
o Does not protect against STIs, including HIV 
o Use condoms (male or female) if you feel at risk of STIs, including HIV 


































































What is an IUD? 
An IUD is an intrauterine device. It is a new and 
improved version of 'the loop' that was used a few 
years ago. 
This is a small , plastic device wh ich is inserted into a woman 's 
womb. The IUD changes the environment in the womb so that 
a male's sperm and a female's eggs can no longer meet -
therefore preventing pregnancy. 
What are the benefits of using an IUD? 
It ca n be used by any woman of reproductive age (14 years 
and older) and can be used wh ile breastfeed ing . 
It ca n also be used by women who are HIV 
pos itive . 
It ca n eas ily be put in place by a nurse or 
doctor. The procedure only takes a few minutes 
and the IUD can stay in place and be effective 
for 10 years. 
It starts working stra ight after insertion . 
If you decide for any reason that you would like to have the IUD 
removed , th is can be done at any time by a doctor or nurse. 
Once an IUD has been inserted, periods are usually regula r 
and users do not gain we ight or have changes in mood. 
Neither a woman nor her partner will be able to feel an IUD 
during intercourse . 
They are convenient as you don't have to remember to take 


















What precautions must I take if I use an 
IUD? 
Although an IUD prevents pregnancy, it does not protect a 
woman from sexually transmitted infections (8Tls) . including 
HIV. A male or female condom must be used to prevent these 
infections. 
Are there any side-effects when using 
an IUD? 
You may have light spotting or bleed ing - this is most 
common at f irst and stops with time. 
Not often, you may have heavier or pro longed periods and 
cramping during the first few months after insertion, but 
usually periods return to normal. 
Can the IUD move around to other 
parts of my body? 
No. It is not poss ible for the IUD to move to other parts of you r 
body as the womb only has one open ing into the birth cana l 
(vag ina). 
Can I lose the IU D? 
This is not like ly. If th is happens, it us ually happens 
in the first months after insert ion . 
How to check that the IUD is in place? 
With 2 fingers you can feel the strings from the IUD 
coming out of the mouth of the womb, where they hang 
into the vag ina. 
What if I want to become pregnant? 
If you would like to become pregnant , you can have the IUD 
removed by the doctor or the nurse at the cl inic. Once the IUD 

















IUDs services are provided at the following clinics: 
Gugulethu CHC-
Family Planning 021 637 1280 
Nyanga Junction 021 6923913 
Nyanga CDC 021 3808031 
Mitchell 's Plain CHC 021 391 5161 
Heideveld CDC 021 6376686 
Cross Road CHC 021 3850260 





































Luhlobo olutsha noluphucukileyo iloop 
nobelusetyenziswa kwiminyaka nje embalwa edlulileyo. 
Yinto nje apha encinane eyenziwe ngeplastiki ethi ifakwe 
iyokuhlala kwisibeleko somntu obhinqileyo. 
I IUD Ie iye itshintshe imo esibelekweni, imo leya yokudibana 
kweqanda lomntu obhinqileyo kunye nembewu yendoda,kutsho 
kungenzeki ukukhulelwa kulowo obhinqileyo. 
Zez,ph nzuzo zokusebe IZlsa UD? 
Ingasetyenziswa nangubani na obhinqileyo osefikisa (iminyaka 
14 nangaphezulu) kwaye noncancisayo umntu uyayisebenzisa. 
Ingasetyenziswa nalibhinqa elinesifo sika gawulayo. 
Ifakeka lula ngumongikazi okanye u gqirha. 
Yonke rento ithabatha imizuzwana nje kwaye i IUD 
ingahlala ikukhusele ithuba leminyaka elishumi. 
Iqalisa ukusebenza kwangoko igqitywa kufakwa. 
Ukuba unqwenela nangasiphi na isizathu ukuyikhupha i IUD, 
lonto ingenziwa nanini na ngumongikazi okanye u gqirha. 
Ngexa ifakiwe i IUD, uyaya exesheni njengesiqhelo, kwaye 
akukho kutyeba okanye isimo sakho asitshintshi. 
Wena okanye iqabane lakho anikwazi ukuphazamiseka yi 
loop xa nisabelana ngesondo. 
Alukho uxanduva lokukhumbula ukulhabalha ipilisi rhoqo okanye uye 
ekliniki kwinyanga ezimbini okanye nlalhu uyokufumana isilofu. 
okuzitha hela 
IUD? 
Zez,ph z to e d" 
ingqalelo xa ndisebenzisa 
Nangona i IUD ikhusela ukungakhulelwa ayikukhuseli kwizifo 

















Makusetyenziswe iikhondoms zababhinqileyo 
nezamadoda ukukhusela ezizifo. 
Ingaba "khona na 1m phumela xa 
usebenzisa UD? 
Unganamaqabaza nje egazi okanye igazi nje. 
Idla ngokwenzeka xa uqala kwaye iye iphele kungekabi phi. 
Ungaya ngamandla exesheni okanye ulhabalhe ixesha elide 
kunesiqhelo kunye nesiluma kwinyanga zokuqala ifakiwe, kodwa 
elhubeni uye ubuyele kwisimo sesiqhelo sokuya exesheni. 
Ingaba UD ngawatyhutyha na 
amanye amalungu omzimba? 
Hayi, ayinakwenzeka lonto ngoba kaloku isibeleko sinendawo 
enye evulekileyo ukuya kwilungu lobumama. 
Ndingap ulukal a a ne UD? 
Ayiqhelekanga lonto, ukuba yenzekile kungaba 
yenzeka kwezinyanga zokuqala isandul u kufakwa. 
Uyijonga njan ukuba isahlel kakuhle UD? 
Ngeminwe nje emibini ungayiva lamisonto ye IUD ithe gqi 
ngaphandle komlomo wesibeleko, apho ijinga khona 
kwilungu lobumama ngaphakathi. 
Ukuba nd;funa ukukhule'wa ke ngoku? 
Ukuba ufuna ukukhulelwa yiza kwiziko lezempilo apho 
iyakuthi ikhutshwe ngugqirha okanye umongikazi. 

















IUDs services are provided at the following clinics: 
Gugulethu CHC -
Family Planning 0216371280 
Nyanga Junction 0216923913 
Nyanga CDC 021 3808031 
Mitchell's Plain CHC 021 391 5161 
Heideveld CDC 0216376686 
Cross Road CHC 021 3850260 





















BRIEF INTERVENTION TO PROMOTE IUD USE AMONG 





Thank you for agreeing to participate in this interview. As I explained earlier, we are 
conducting a study to find out how to increase the use of the intrauterine device, or 
the IUD/loop, among women in Cape Town. In this interview, I will ask you about 
yourself, your background, your history of pregnancies, contraceptive use and your 
sexual history.  
 
Everything we talk about is confidential. If there are any questions that you feel 
uncomfortable answering, feel free to tell me to skip those. If at anytime you don’t 
want to continue with the interview, please let me know. 
 
This interview will take about ½ hour. We really appreciate you agreeing to be part of 
this study and sharing personal information that may contribute to improving family 














WRITE THE PARCIPANT’S STUDY IDENTIFICATION NUMBER ON THE TOP RIGHT CORNER OF 
EACH PAGE OF THE INTERVIEW – EITHER BEFORE YOU START OR AFTER YOU COMPLETE 
THE INTERVIEW. THIS IS IMPORTANT IN THE EVENT THAT PAGES BECOME DETACHED. 
 
PLEASE WRITE THE PARTICIPANT’S NAME IN CLEAR BLOCK CAPITAL LETTERS. IF THE 
PARTICIPANT HAS A FOLDER, PLEASE BE SURE TO PLACE A STICKER IN THE “PARTICIPANT 































































# Item Answer Key 
A Participant Name  
_____________  ________________ 
Surname               Name 
 
B Participant Phone Number 
_________________________ 




D Study ID Number ___ ___ ___ 
E Enrolment Site 1 = Gugulethu CHC 
2 = Hannan Crusaid 
F Date  
___ ___ /___ ___ /___ ___ 
   Day       Month      Year 
 
G Interviewer  
_____________  ________________ 
Surname               Name 
 
H Interviewer: Does the participant meet the study eligibility 
criteria? 
0 = No  
1 = Yes 
I Interviewer: Has the participant completed the informed 
consent process? 
0 = No  
1 = Yes 
Socio-demographic Information 
1 How old are you?  
Age in years: _________ 
2 What is the primary language you speak at home? 1 = IsiXhosa 
2 = IsiZulu 
3 = Afrikaans 
4 = English 
5 = Other (specify):_____________ 
3 Are you working full-time, working part-time, studying or 
not working at all? 
 
1 = Full-time – Specify type of work: 
___________________________ 
 
2 = Part-time – Specify type of work: 
___________________________ 
 
3 = Studying 
 
4= Not working 
4 What is the highest level of schooling or education that 
you have completed? 
 
IF P RESPONDS IN “STANDARD” CONVERT TO 
GRADE = STANDARD + 2 
 
Grade : _____  
 
Post Secondary (explain): 
___________________ 
 
5 Including yourself, how many people live in your 
household? 












6 Do you have electricity in your house? 0 = No 
1 = Yes 
7 Do you have a toilet in your house? 0 = No  
1 = Yes 
8 What kind of home do you live in? 
 
READ CHOICES 
1 = Shack/informal dwelling  
2 = Home ownership  
3 = Flat/council home  
4 = Other - specify:_____________ 
9 How many times have you been pregnant?  
Interviewer:  If the answer is 0 SKIP to Question 13 
Enter Number: _____ 
-9 = Refused 
10 How many of your pregnancies ended in a live birth i.e. 
the baby was born alive? 
Enter Number: _____ 
-9 = Refused 
11 Were you trying to become pregnant when you had your 
last child? 0 = No  
1 = Yes 
12 Have you ever had a TOP, or termination of pregnancy, 
sometimes called an abortion? 
 
0 = No  
1 = Yes 
-9 = Refused 
 
13 Do you intend to have any or more children in the future?  
Interviewer: If the answer is No SKIP to Question 15 
0 = No  
1 = Yes 
2 = Don’t know/Not sure 
-9 = Refused 
14 How many more children do you intend to have? Enter Number: _________ 
Medical History 
Now I would like to ask you some questions about your medical history 
15 Have you ever been tested for HIV? 
Interviewer: If the answer is No or Refused SKIP to 
Question 18 
0 = No  
1 = Yes 
- 9 = Refused 
16 What is your HIV status? 
Interviewer: If the answer is Negative or Don’t know or 
Refused SKIP to Question 18 
0 = Negative 
1 = Positive 
2 = Don’t know 
-9 = Refused 
17 Are you on antiretroviral drugs (ARVs)? 0 = No  
1 = Yes 
-9 = Refuse to answer 
18 Have you ever had a Pap smear?  
A Pap smear is a test to detect abnormal cancer cells in 
the mouth of the womb that may lead to cancer. When 
performing this test the doctor or nurse places an 
instrument called a speculum (spoon) in the woman’s 
vagina so that he/she can see the mouth of the womb 




0 = No  
1 = Yes 
2 = Don’t know/Not sure 
- 9 = Refused 
19 Within the last 3 months, have you been told you have 
an STI?   
0 = No  
1 = Yes 












20 Do you have bleeding between menstrual periods that is 
unusual for you or bleeding after having sex? 
0 = No  
1 = Yes 
-9 = Refused 
Sexual activity and Contraceptive History 
Now I would like to ask you some questions about your past sexual activity and contraceptive use 
21 How old were you when you first had sexual (vaginal) 
intercourse? 
Age in years: _________ 
22 How many sexual partners have you had in the past 
year? 
Enter Number: __________ 
23 Are you currently in a sexual relationship? 
 
Interviewer: If the answer is No SKIP to Question 28 
 
0 = No  
1 = Yes 
-9 = Refused 
24 How would you describe this relationship?  
 
READ CHOICES 
1 = Married 
2 = Not married, living together  
3 = Girlfriend/boyfriend (not living 
together) 
4 = Other specify:____________ 
 
25 Have you ever discussed family planning or 
contraception with your partner or husband? 
Interviewer: If the answer is No SKIP to Question 27 
 
0 = No  
1 = Yes 
26 How does your partner or husband feel about family 
planning or using contraception? 
 
READ CHOICES 
1 = Negative 
2 = Neutral 
3 = Positive 
4 = Don’t know 
  
27 Does your partner or husband have more, less or the 
same amount of education that you do?  
1 = Less 
2 = More 
3 = Same 
4 = Don’t know 
 
28 Have you ever used a contraceptive method? 
Interviewer: If the answer is No SKIP to Question 32 
What contraceptive method(s) have you used? 
 
READ CHOICES  
 
a. Oral contraceptive pill 
b. 2-month injectable 
c. 3-month injectable 
d. IUD/loop 
e. Male sterilisation 
f. Female condom 
g. Male condom 
h. Diaphragm 
i. Other method – specify: _________________ 
0 = No  
1 = Yes 




a. 0           1 
b. 0           1 
c. 0           1 
d. 0           1 
e. 0           1 
f. 0           1 
g. 0           1 
h. 0           1 
 
30 Have you used a contraceptive method in the past 12 
months? 
Interviewer: If the answer is No SKIP to Question 32 
 
0 = No  












31 What contraceptive method(s) have you used? 
 
READ CHOICES  
 
a. Oral contraceptive pill 
b. 2-month injectable 
c. 3-month injectable 
d. IUD/loop 
e. Male sterilisation 
f. Female condom 
g. Male condom 
h. Diaphragm 
       i.    Other method – specify: _________________ 
      No          Yes 
 
 
a. 0           1 
b. 0           1 
c. 0           1 
d. 0           1 
e. 0           1 
f. 0           1 
g. 0           1 
h. 0           1 
           
Health Locus of Control 
I’m going to read to you a list of belief statements about pregnancy with which you may agree or 
disagree. For each statement there is a scale which ranges from strongly disagree (1) to strongly 
agree (6). For each item we would like you to choose the number that represents how much you agree 
or disagree with that statement. This is a measure of your personal beliefs and there are no right or 
wrong answers. 
 
INTERVIEWER: Please make sure that EVERY ITEM is answered and that you circle ONLY ONE 
number per item.  
32 It is my own behaviour which determines when or if I 
become pregnant. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
33 Often I feel that no matter what I do, if I am going to 
become pregnant, I will become pregnant. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
34 It seems that whether or not I become pregnant is 
greatly influenced by chance. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
35 I am in control of whether or not I become pregnant. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
36 If I become pregnant accidently, it is my own fault. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 












37 When it comes to whether or not I become pregnant, I 
just have to let nature run its course. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
38 Whether or not I become pregnant is largely a matter of 
good fortune. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
39 Whether or not I become pregnant depends on if I use 
contraception. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
40 If I take contraception, I can avoid becoming pregnant. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
41 Even if I take contraception, it’s easy to become 
pregnant. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
42 If it’s meant to be, I will become pregnant. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
43 If I take contraception, I can prevent pregnancy. 
 
[READ CHOICES AND SHOW CARD] 
1 = Strongly disagree 
2 = Moderately disagree 
3 = Slightly disagree 
4 = Slightly agree 
5 = Moderately agree 
6 = Strongly agree 
Contraceptive Preferences 
Each item below is a statement about contraception with which you may agree or disagree. Beside 
each statement is a scale which ranges from not important (1) to very important (3). For each item we 
would like you to choose the number that represents how you feel about each statement. This is a 
measure of your personal beliefs and there are no right or wrong answers. 
 
44 The following characteristics of a contraceptive are 













 a. Effective at preventing pregnancy 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 b. Effective at preventing HIV/STIs 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 c. Undetectable by male partner 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 d. Not necessary to remember daily or with sexual 
activity 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 e. Lasts for a long time without requiring a medical visit 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 f. Does not require a medical provider to receive 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 g. Is “natural”/does not contain hormones 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 h. Does not change menstrual bleeding patterns 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 i. Causes menses to stop 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 j. Does not cause weight-related side-effects 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 k. Does not interact with ART 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
 l. Does not cause mood changes 
 
[READ CHOICES AND SHOW CARD] 
1 = Not important 
2 = Somewhat important 
3= Very important 
45 If a contraceptive had the following characteristics, it 




 a. No effect on preventing HIV/STIs 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
 b. Male partner aware of method 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
 c. Must remember to use at every sex act or take daily 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 












 d. Requires an injection 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
 e. Requires a physician/medical provider to provide 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
 f. Lasts for months or longer 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
 g. May interact with HIV infection or ART 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
 h. Causes irregular menstrual bleeding 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
 i. Causes menstrual bleeding to stop 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
 j. May cause mood changes 
 
[READ CHOICES AND SHOW CARD] 
1 = Not a problem 
2 = Somewhat a problem 
3= Very much a problem 
46 Have you ever heard of the IUD or loop?  0 = No  
1 = Yes 
Participant awareness and attitude toward the IUD 
An IUD or loop is a small T-shaped plastic and copper device that is inserted into the womb. It protects 
against pregnancy for 10 to 12 years. The IUD may be removed if future childbearing is desired with 
immediate return of fertility.  IUD insertion and removal can be done easily within a clinic. The most 
common side-effect associated with IUD use is change in menstrual bleeding. 
47 Is the IUD/loop a method you would ever consider 
using? 
0 = No  
1 = Yes 
2= Maybe 
48 Do you know anyone who uses or has used an 
IUD/loop?  
 
Interviewer: If the answer is No SKIP to Question 50 
0 = No  
1 = Yes 
49 Who do you know that has used or uses an IUD?  




50 Has a medical provider ever discussed or offered an IUD 
to you?  
 
Interviewer: If the answer is No SKIP to Question 52 
0 = No  
1 = Yes 
51 Which type of provider? 
 
READ CHOICES AND CIRCLE ALL THAT APPLY 
 
1= Sister/Nurse 
2 = Doctor 
3 = Other 
Specify: ______________ 
52 If you could, would you be interested in receiving an IUD 
today? 
0 = No  
1 = Yes 

































IUD uptake – Follow Up Measures 
53 Did the participant go to Family Planning 
to make an appointment for IUD 
insertion? 
0 = No  
1 = Yes 
54 Did the participant get the IUD inserted?  
0 = No  
1 = Yes 
 
___ ___ /___ ___ /___ ___ 
   Day       Month      Year 
 
55 Did the participant go to Family Planning 
to get information about the IUD or other 
contraception? 
0 = No  
1 = Yes 
 
 
___ ___ /___ ___ /___ ___ 
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Contraception: Instructions to Authors 
 
Editorial Policies  
 
Contraception invites concise reports of original research in the experimental and clinical 
aspects of all areas of contraception. The purpose of this journal is to provide a medium for 
the rapid communication of advances and new knowledge in this important field. The Editor 
anticipates receiving manuscripts from workers in the following areas of research: chemistry, 
biochemistry, physiology, endocrinology, biology, the medical sciences, and demography. 
Publication of original papers within 90 days of manuscript receipt is plan ed. Authors will 
be advised of disposition of the manuscript within 30 days of receipt. 
 
Manuscript Submission Process ONLINE  
 
All manuscripts must be submitted electronically through the Elsevier Editorial System 
website (www.ees.elsevier.com/contraception). Select: "New Manuscript". Author guidance 
is provided for creating and uploading all files and data. The system automatically generates 
an electronic (PDF) proof, which is then sent to the Editorin-Chief and to designated 
reviewers. All correspondence about submitted manuscripts also will be handled by e-mail 
through the EES.  
 
The requirement for manuscripts submitted to Contraception conform to the "Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals" established by the 
International Committee of Medical Journal Editors and published in Annals of Internal 
Medicine 1988; 108:258-65. 
 
Trial and research guidelines. The following guidelines must be adhered to when 
formulating the study. Upon submission of the manuscript, authors are to indicate the type of 
trial/research used on the Author Checklist.  
 Randomized controlled trials. Authors are to consult the CONSORT statement. 
(Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT 
Statement: Revised recommendations for improving the quality of reports of parallel-
group randomized trials. JAMA 2001;285:1987-91) A flow-chart as a figure must be 
submitted with the manuscript. www.consort-statement.org  
 Meta-analysis and systematic reviews of randomized controlled trials. Authors 
are to consult the QUOROM statement. (Moher D, Cook DJ, Eastwood S, Olkin I, 
Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of 
randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-
Analyses. Lancet 1999;354:1896-900.) www.thelancet.com  
 Meta-analysis and systematic review of observational studies. Authors are to 
consult the MOOSE guidelines. (Stroup DF, Berlin JA, Morton SC, et. al., for the 












analysis of observational studies in epidemiology: A proposal for reporting. JAMA 
2000;283:2008-12." www.jama.ama-assn.org  
 Diagnostic tests. Authors are to consult the STARD Initiative. (Bossuyt, PM, 
Reitsma, JB, Bruns, DE, et. al. Towards complete and accurate reporting of studies of 
diagnostic accuracy: The STARD Initiative. Clin Chem 2003;49:1-6.) 
www.clinchem.org 
 
Previous publication. If a report by the same author(s) has been previously published in any 
medium that deals in any respect whatever with the same patients, same animals, same 
laboratory experiments, or same data, in part or in full, as those reported in the manuscript 
being submitted, two reprints of the article or two copies of the manuscript, be it a full-length 
report or an abstract, must be submitted with the manuscript. The author(s) should inform the 
Editor of the circumstances, similarities, and differences of the reports. This requirement also 
applies to the submission of a manuscript in which a few different patients, animals 
laboratory experiments, or data were added to those reported in a previous publication or in a 
submitted or accepted manuscript. Articles previously published in another language will not 
be considered.  
 
Human and animal experimentation. It is assumed by the Editor that manuscripts 
emanating from a particular institution are submitted with the approval of the requisite 
authority. Human experimentation that requires local institutional approval must have this 
approval before the experiment is started and approval must be so indicated in the Methods 
section of the submitted manuscript. Reports of experiments on animals must state in the 
Methods section of the manuscript that the guidelines for the care and use of the animals 
approved by the local institution were followed. The species of nonhuman animals must be 
named in the title, abstract, and key words of the manuscript.  
 
Authorship. For manuscripts with two or more authors, each author must qualify by having 
participated actively and sufficiently in the study that is being performed and reported. The 
inclusion of each author in the authorship list of a report is based only (1) on substantial 
contributions to (a) concept and design, or analysis and interpretation of data and (b) drafting 
the manuscript or revising it critically for important intellectual content; and (2) on final 
approval by each author of the version of the manuscript. Conditions 1 (a and b) and 2 must 
both be met. Others contributing to the work should be recognized separately in an 
Acknowledgment. In the covering letter that accompanies the submitted manuscript, it must 
be confirmed that all authors fulfilled both conditions.  
 
Preparation of Manuscripts. The electronic manuscript, tables, and figures must be 
submitted to the Journal at www.ees.elsevier.com/contraception. Submit figures online in a 
separate file in EPS, JPEG, or TIFF format (minimum 300 dpi). Figures should not be 
embedded in the manuscript document. If a figure has been previously published, by you or 
by others, obtain permission and acknowledge fully in the figure legend. Remove all patient 
identifying marks (Protection of Patients' Rights to Privacy).  
 
Manuscripts must be typed double-spaced. Also include five or six keywords and a short 
running title.  
 
A manuscript length of 5-9 pages, including tables, figures, and references is suggested. 













Title Page. The text of the article should include the following: a STRUCTURED 
ABSTRACT (with the following subheadings: Background, Study Design, Results, 
Conclusions) (approximately 150 words) INTRODUCTION, MATERIALS and METHODS, 
RESULTS, DISCUSSION, and ACKNOWLEDGMENT/ NOTES.  
 
Text. The text of the article should include the following: ABSTRACT (approximately 150 
words), INTRODUCTION, MATERIALS and METHODS, RESULTS, DISCUSSION, and 
ACKNOWLEDGMENT/FOOTNOTES (this is where the author name and address for 
reprint requests should be listed).  
 
Figures. All figures (photographs, drawings, diagrams, charts) should be clear, easily legible 
and cited consecutively by Arabic numerals in the text (Figure 1, Figure 2, etc.). Legends 
should contain sufficient detail to permit figure interpretation without reference to the text. 
Units should be indicated in the figures. The cost of color reproduction in the print journal is 
$400 for the first figure on a page. The cost for each additional color figure on the page is 
$150. Multi-part figures are considered one figure. All color figures will appear on the web 
site (www.contraceptionjournal.org) at no cost to the authors.  
 
Tables. Tables must be concise, as simple as possible, and cited consecutively by Arabic 
numerals in the text (Table 1, Table 2, etc.). Each table should be titled and submitted as a 
separate file. The title of each table should clearly indicate the nature of the contents. 
Sufficient detail should be included in the table footnote to facilitate interpretation.  
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Manuscripts Submitted to Biomedical Journals" promulgated by the International Committee 
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Each reference must be cited. Referenced articles must have been published in peer-review 
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